CASEID,PRIMARYID,CASEVERSION,I_F_CODE,EVENT_DT,MFR_DT,INIT_FDA_DT,FDA_DT,REPT_COD,AUTH_NUM,MFR_NUM,MFR_SNDR,LIT_REF,AGE,AGE_COD,AGE_GRP,SEX,E_SUB,WT,WT_COD,REPT_DT,TO_MFR,OCCP_COD,REPORTER_COUNTRY,OCCR_COUNTRY,DRUGNAME,PT,PRIMARYID_OUTC,OUTC_COD,PRIMARYID_RPSR,RPSR_COD,PRIMARYID_THER,DSG_DRUG_SEQ,START_DT,END_DT,DUR,DUR_COD,PRIMARYID_INDI,INDI_DRUG_SEQ,INDI_PT
10495703,104957033,3,F,,20180207,20141003,20180213,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-21429014,BRISTOL MYERS SQUIBB,,41,YR,,M,Y,,,20180213,,OT,CA,CA,SUSTIVA,Drug interaction;Virologic failure,104957033,OT,,,,,,,,,104957033,1,HIV infection
11307801,1130780115,15,F,,20180307,20150724,20180321,EXP,,DE-ROCHE-1495718,ROCHE,", PETERSEN J, GSCHWANTLER M, CORNBERG M, ZOUFALY A, BERG T, NAUMANN U, VAN DER VALK M, WEILAND O, JIMENEZ-EXPOSITO M, AND ZEUZEM S DACLATASVIR PLUS SOFOSBUVIR WITH OR WITHOUT RIBAVIRIN IN PATIENTS INFECTED WITH HCV GENOTYPE 3: INTERIM RESULTS OF A MULTICENTER COMPASSIONATE USE PROGRAM IN EUROPE. ZEITSCHRIFT FUR GASTROENTEROLOGIE 2015 AUG;53(8):-.",,,,,Y,,,20180321,,MD,DE,DE,EFAVIRENZ.,Abdominal pain;Acute kidney injury;Anaemia;Anal cancer;Arthralgia;Blood creatinine increased;Calculus urinary;Circulatory collapse;Clostridium difficile colitis;Dehydration;Dermatitis allergic;Diarrhoea;Drug withdrawal syndrome;Dyspnoea;Erysipelas;Fatigue;Fluid overload;Gastrointestinal disorder;Gastrointestinal infection;General physical health deterioration;Haemorrhoidal haemorrhage;Headache;Hepatic encephalopathy;Hepatic failure;Hepatobiliary disease;Hepatocellular carcinoma;Hypersensitivity vasculitis;Hypertension;Hyponatraemia;Infection;Lactic acidosis;Liver disorder;Lymphoedema;Mental disorder;Myocardial infarction;Nausea;Neoplasm;Neutropenia;Pancreatitis acute;Pancytopenia;Peritonitis bacterial;Portal vein thrombosis;Sleep disorder;Soft tissue infection;Somnolence;Streptococcal sepsis;Vertigo,1130780115,DE,,,,,,,,,1130780115,1,Chronic hepatitis C
11762842,117628424,4,F,20120824,20130416,20151120,20180131,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-18822858,BRISTOL MYERS SQUIBB,,0,DY,,,Y,2.52,KG,20180131,,OT,BR,BR,EFAVIRENZ.,Foetal exposure during pregnancy;Infection;Jaundice neonatal;Premature baby,117628424,HO,,,117628424,1,20080919,20090115,,,117628424,1,Product used for unknown indication
11858629,118586295,5,F,,20180215,20151222,20180228,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2007-000002,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20180228,,CN,FR,FR,SUSTIVA,Foetal exposure during pregnancy;Heart disease congenital,118586295,OT,,,118586295,1,20051201,20071211,,,118586295,1,Product used for unknown indication
11991033,119910333,3,F,,20180226,20160202,20180310,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-004939,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20180310,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,119910333,OT,,,,,,,,,119910333,1,Product used for unknown indication
12687626,126876268,8,F,20160802,20171227,20160825,20180104,EXP,,UG-GILEAD-2016-0227055,GILEAD,,37,YR,A,M,Y,49,KG,20180104,,OT,UG,UG,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Acute kidney injury;Anaemia,126876268,HO,,,126876268,1,20140319,20160801,,,126876268,1,Kaposi's sarcoma AIDS related
12692464,126924642,2,F,201006,20180314,20160829,20180329,EXP,,CA-CIPLA LTD.-2016CA17600,CIPLA,"AWORTWE C, MAKIWANE M, REUTER H, MULLER C, LOUW J, ROSENKRANZ. CRITICAL EVALUATION OF CAUSALITY ASSESSMENT OF HERB-DRUG INTERACTIONS IN PATIENTS",,,,,Y,,,20180329,,OT,ZA,CA,EFAVIRENZ.,Drug interaction;Virologic failure,126924642,OT,,,,,,,,,126924642,1,HIV infection
12817795,128177953,3,F,20160902,20180129,20161005,20180202,EXP,,FR-GILEAD-2016-0235829,GILEAD,,52,YR,A,M,Y,68,KG,20180202,,OT,FR,FR,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Rectal cancer,128177953,HO,,,128177953,1,20101105,,,,128177953,1,HIV infection
12978291,129782915,5,F,20160222,20180131,20161128,20180202,EXP,,LS-JNJFOC-20161121675,JANSSEN,,42,YR,A,M,Y,51,KG,20180202,,MD,LS,LS,EFAVIRENZ.,Hypokalaemia;Pancytopenia,129782915,OT,,,129782915,1,20151211,2016,,,129782915,1,Tuberculosis
13014538,130145384,4,F,,20180313,20161209,20180321,EXP,,PHHY2015BR064616,NOVARTIS,,,,,F,Y,54,KG,20180321,,MD,BR,BR,EFAVIRENZ.,Alopecia;Blood iron increased;Chills;Diarrhoea;Dizziness;Drug intolerance;Dysphagia;Haemoglobin abnormal;Inappropriate schedule of drug administration;Malaise;Nausea;Poisoning;Retching;Serum ferritin abnormal;Serum ferritin decreased;Serum ferritin increased;Vomiting;Weight increased;Wrong technique in product usage process,130145384,OT,,,,,,,,,130145384,1,Haemoglobinopathy
13094483,130944832,2,F,,20180105,20170106,20180116,EXP,IT-MINISAL02-390000,IT-MYLANLABS-2017M1000021,MYLAN,"MICHELINI Z, GALLUZZO CM, PIRILLO MF, FRANCISCI D, ANTONI AD, VIVARELLI A ET AL.. HIV-1 DNA DYNAMICS AND VARIATIONS IN HIV-1 DNA PROTEASE AND REVERSE TRANSCRIPTASE SEQUENCES IN MULTIDRUG RESISTANT PATIENTS DURING SUCCESSFUL RALTEGRAVIR-BASED THERAPY. JOURNAL OF MEDICAL VIROLOGY. 2016;88:2115-2124",45,YR,,,Y,,,20180116,,OT,IT,IT,EFAVIRENZ.,Multiple-drug resistance;Viral mutation identified,130944832,OT,,,,,,,,,130944832,1,HIV infection
13175954,131759544,4,F,20170103,20171227,20170201,20180103,EXP,,MW-GILEAD-2017-0253792,GILEAD,,28,YR,A,F,Y,56.8,KG,20180103,,OT,MW,MW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Drug-induced liver injury,131759544,DE,,,131759544,1,20161116,20170102,,,131759544,1,Kaposi's sarcoma AIDS related
13583409,135834092,2,F,20170407,20180125,20170526,20180207,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-044557,BRISTOL MYERS SQUIBB,,58,YR,,M,Y,57,KG,20180207,,MD,FR,FR,SUSTIVA,Abnormal behaviour;Aggression;Irritability,135834092,OT,,,135834092,1,20120104,20170407,,,135834092,1,Product used for unknown indication
13631960,136319604,4,F,20170525,20171227,20170608,20180104,EXP,,KE-GILEAD-2017-0276578,GILEAD,,33,YR,A,M,Y,59,KG,20180104,,OT,KE,KE,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Acute kidney injury,136319604,HO,,,136319604,1,20170227,20170524,,,136319604,1,Kaposi's sarcoma AIDS related
13684980,136849805,5,F,20170608,20171227,20170623,20180104,EXP,,KE-GILEAD-2017-0279230,GILEAD,,53,YR,A,M,Y,56.4,KG,20180104,,OT,US,KE,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Anaemia,136849805,HO,,,136849805,1,20170322,20170511,,,136849805,1,Acquired immunodeficiency syndrome
13716882,137168823,3,F,2017,20180227,20170705,20180302,EXP,,LS-JNJFOC-20170700531,JANSSEN,,38,YR,A,M,Y,54,KG,20180302,,MD,LS,LS,EFAVIRENZ.,Cardiac failure congestive;Electrocardiogram QT prolonged;Hypokalaemia;Hypovolaemic shock;Pneumonia;Pulmonary oedema;Respiratory failure,137168823,OT,,,137168823,1,20170112,20170626,,,137168823,1,Tuberculosis
13756156,137561563,3,F,20170424,20180305,20170714,20180313,EXP,,US-EXELIXIS-XL18417009762,EXELIXIS,,65,YR,,M,Y,51.66,KG,20180313,,MD,US,US,EFAVIRENZ W/LAMIVUDINE/TENOFOVIR DISOPROXIL F,Atrioventricular block complete;Sinus bradycardia,137561563,HO,,,137561563,1,20140121,20170424,,,137561563,1,Neoplasm
13980436,139804362,2,F,,20180126,20170918,20180203,EXP,,UG-HETERO CORPORATE-HET2017UG00185,HETERO,,28,YR,,F,Y,,,20180203,,OT,UG,UG,EFAVIRENZ.,Drug-induced liver injury;Exposure during pregnancy;Foetal death,139804362,OT,,,139804362,1,20170309,20170313,,,139804362,1,HIV infection
14017096,140170962,2,F,20170309,20180125,20170927,20180208,EXP,,UG-MYLANLABS-2017M1058627,MYLAN,,,,,M,Y,3,KG,20180208,,OT,UG,UG,EFAVIRENZ.,Foetal exposure during pregnancy;Stillbirth,140170962,DE,,,140170962,1,20170309,20170313,,,140170962,1,HIV infection
14018138,140181382,2,F,,20180126,20170928,20180208,EXP,,UG-CIPLA LTD.-2017UG17389,CIPLA,,,,,,Y,,,20180208,,CN,UG,UG,EFAVIRENZ.,Exposure during pregnancy;Stillbirth,140181382,OT,,,140181382,1,20170309,20170313,,,140181382,1,HIV infection
14018140,140181402,2,F,20170509,20180126,20170928,20180208,EXP,,UG-CIPLA LTD.-2017UG17700,CIPLA,,,,,,Y,,,20180208,,CN,UG,UG,EFAVIRENZ.,Foetal exposure during pregnancy;Liver injury,140181402,DE,,,,,,,,,140181402,1,Product used for unknown indication
14107673,141076733,3,F,20171013,20180221,20171019,20180226,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-094025,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20180226,,OT,BR,BR,EFAVIRENZ.,Foetal distress syndrome;Foetal exposure during pregnancy;Premature baby,141076733,OT,,,141076733,1,20170810,20171013,,,141076733,1,Prophylaxis against HIV infection
14107707,141077073,3,F,20170824,20180221,20171019,20180226,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-088415,BRISTOL MYERS SQUIBB,,23,YR,,F,Y,56,KG,20180226,,OT,BR,BR,EFAVIRENZ.,Maternal exposure during pregnancy;Premature delivery;Premature labour;Vulvovaginal candidiasis,141077073,OT,,,141077073,1,20170810,20170922,,,141077073,1,HIV infection
14111103,141111033,3,F,,20180112,20171020,20180119,EXP,,FR-VIIV HEALTHCARE LIMITED-FR2017GSK161427,VIIV,,37,YR,,F,Y,,,20180119,,CN,US,FR,SUSTIVA,Beta haemolytic streptococcal infection;Cytomegalovirus enterocolitis;Headache;Hepatitis B;Live birth;Maternal exposure during pregnancy;Metrorrhagia;Placental disorder;Pulmonary arterial hypertension;Threatened labour;Uterine contractions during pregnancy,141111033,OT,,,141111033,3,20150608,20150608,,,141111033,1,HIV infection
14111220,141112203,3,F,,20180112,20171020,20180119,EXP,,FR-GLAXOSMITHKLINE-FR2017GSK161427,GLAXOSMITHKLINE,,37,YR,,F,Y,,,20180119,,CN,US,FR,SUSTIVA,Beta haemolytic streptococcal infection;Cytomegalovirus enterocolitis;Headache;Hepatitis B;Live birth;Maternal exposure during pregnancy;Metrorrhagia;Placental disorder;Pulmonary arterial hypertension;Threatened labour;Uterine contractions during pregnancy,141112203,HO,,,141112203,3,20150608,20150608,,,141112203,1,HIV infection
14111391,141113913,3,F,20170726,20180131,20171020,20180202,EXP,,UG-GILEAD-2017-0299190,GILEAD,,42,YR,A,M,Y,65,KG,20180202,,MD,UG,UG,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Tibia fracture,141113913,HO,,,141113913,1,20120309,,,,141113913,1,HIV infection
14117376,141173764,4,F,201404,20180117,20171023,20180119,EXP,,IT-GILEAD-2017-0300028,GILEAD,,27,YR,A,F,Y,,,20180119,,CN,IT,IT,EFAVIRENZ.,Drug resistance;End stage renal disease;Pathogen resistance;Prescribed overdose;Treatment noncompliance;Viral mutation identified;Virologic failure,141173764,OT,,,141173764,1,201505,201404,,,141173764,1,HIV infection
14132073,141320733,3,F,20150608,20171220,20171027,20180104,EXP,,FR-AUROBINDO-AUR-APL-2017-42194,AUROBINDO,,0,DY,,M,Y,2.64,KG,20180103,,MD,FR,FR,SUSTIVA,Foetal exposure during pregnancy;Foetal growth restriction;Low birth weight baby;Small for dates baby,141320733,OT,,,141320733,5,20150608,20150608,,,141320733,1,HIV infection
14165463,141654634,4,F,201404,20180329,20171107,20180331,EXP,,IT-AUROBINDO-AUR-APL-2017-43260,AUROBINDO,,27,YR,,F,Y,,,20180331,,OT,IT,IT,EFAVIRENZ.,Drug resistance;End stage renal disease;Pathogen resistance;Prescribed overdose;Treatment noncompliance;Viral mutation identified;Virologic failure,141654634,OT,,,,,,,,,141654634,1,HIV infection
14171609,141716093,3,F,201404,20180112,20171108,20180130,EXP,,IT-MYLANLABS-2017M1069639,MYLAN,,27,YR,,F,Y,,,20180130,,CN,IT,IT,EFAVIRENZ.,Drug resistance;End stage renal disease;Pathogen resistance;Prescribed overdose;Treatment noncompliance;Viral mutation identified;Virologic failure,141716093,OT,,,141716093,1,201505,201505,,,141716093,1,Antiretroviral therapy
14186638,141866385,5,F,2014,20180117,20171114,20180208,EXP,,IT-VIIV HEALTHCARE LIMITED-IT2017GSK173670,VIIV,,27,YR,,F,Y,,,20180208,,CN,IT,IT,EFAVIRENZ.,Drug ineffective;Drug resistance;End stage renal disease;Pathogen resistance;Prescribed overdose;Renal failure;Renal impairment;Secondary hypertension;Treatment noncompliance;Viral mutation identified;Virologic failure,141866385,OT,,,141866385,4,201505,,,,141866385,1,HIV infection
14207139,142071393,3,F,,20171213,20171121,20180315,EXP,,BR-HETERO CORPORATE-HET2017BR00352,HETERO,,,,,M,Y,,,20180315,,OT,BR,BR,EFAVIRENZ.,Foetal exposure during pregnancy;Talipes,142071393,CA,,,142071393,1,20170705,20171108,,,142071393,1,HIV infection
14210539,142105394,4,F,,20180103,20171121,20180112,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-103450,BRISTOL MYERS SQUIBB,,,,,,Y,,,20180112,,CN,GB,GB,EFAVIRENZ.,Lip and/or oral cavity cancer,142105394,OT,,,,,,,,,142105394,1,Antiretroviral therapy
14211380,142113802,2,F,20111120,20180208,20171121,20180215,EXP,,US-BAYER-2017-220088,BAYER,,44,YR,A,M,Y,,,20180215,,CN,US,US,SUSTIVA,Neuropathy peripheral,142113802,OT,,,142113802,1,20060321,20060328,,,142113802,1,Urinary tract infection
14221025,142210252,2,F,,20180108,20171124,20180110,EXP,,TR-GILEAD-2017-0306400,GILEAD,,41,YR,A,M,Y,,,20180110,,MD,TR,TR,EFAVIRENZ.,Mesangioproliferative glomerulonephritis,142210252,DE,,,,,,,,,142210252,1,HIV infection
14221665,142216653,3,F,20170823,20180202,20171124,20180213,EXP,,PHHY2017CO172327,NOVARTIS,,57,YR,,M,Y,54,KG,20180213,,CN,COUNTRY NOT SPECIFIED,CO,EFAVIRENZ.,Arthralgia;Decreased immune responsiveness;Platelet count decreased,142216653,OT,,,142216653,1,20140616,,,,142216653,1,Chronic myeloid leukaemia
14237552,142375522,2,F,,20180112,20171129,20180118,EXP,,PL-GILEAD-2017-0307146,GILEAD,,45,YR,A,M,Y,,,20180118,,MD,PL,PL,EFAVIRENZ.,Immune reconstitution inflammatory syndrome,142375522,HO,,,142375522,1,20171113,20171116,,,142375522,1,Product used for unknown indication
14244884,142448843,3,F,201404,20171227,20171201,20180105,EXP,IT-MINISAL02-436103,IT-009507513-1711ITA010779,MERCK,"TARTAGLIA A, ET AL.. SUCCESSFUL TREATMENT WITH TENOFOVIR ALAFENAMIDE OF A HIV/HEPATITIS B VIRUS COINFECTED PATIENT WITH HIV AND HEPATITIS B VIRUS DRUG RESISTANCE, END-STAGE RENAL DISEASE ON HAEMODIALYSIS.. AIDS. 2017;31(16):2314-5",27,YR,,F,Y,,,20180105,,CN,IT,IT,EFAVIRENZ.,End stage renal disease;Pathogen resistance;Treatment noncompliance;Virologic failure,142448843,OT,,,142448843,9,201505,201404,,,142448843,1,HIV infection
14266076,142660765,5,F,201404,20180213,20171209,20180226,EXP,IT-MINISAL02-437307,PHHY2017IT167635,NOVARTIS,,27,YR,,F,Y,,,20180226,,OT,IT,IT,EFAVIRENZ.,End stage renal disease;Pathogen resistance;Prescribed overdose;Virologic failure,142660765,OT,,,,,,,,,142660765,1,HIV infection
14283035,142830352,2,F,20071111,20180215,20171213,20180220,EXP,,FR-GILEAD-2017-0310074,GILEAD,,,,,F,Y,,,20180220,,CN,GB,FR,SUSTIVA,Foetal exposure during pregnancy;Heart disease congenital,142830352,CA,,,142830352,2,20051201,20071211,,,142830352,1,Antiretroviral therapy
14297931,142979312,2,F,20171116,20180203,20171218,20180215,EXP,,PL-MYLANLABS-2017M1079437,MYLAN,KRANKOWSKA D.. MAOPYTKOWO HISTORIA PACJENTA Z HIV.,45,YR,,M,Y,,,20180214,,MD,PL,PL,EFAVIRENZ.,Death;Immune reconstitution inflammatory syndrome,142979312,HO,,,142979312,1,20171113,20171116,,,142979312,1,HIV infection
14301744,143017442,2,F,20171116,20180122,20171219,20180205,EXP,,PL-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-112135,BRISTOL MYERS SQUIBB,KRANKOWSKA D. THROMBOCYTOPENIA- PATIENT HISTORY,45,YR,,M,Y,,,20180205,,MD,PL,PL,EFAVIRENZ.,Death;Immune reconstitution inflammatory syndrome;Thrombocytopenia,143017442,OT,,,143017442,1,20171113,20171116,,,143017442,1,HIV infection
14332029,143320292,2,F,,20171218,20171228,20180109,EXP,,BR-MYLANLABS-2017M1078574,MYLAN,,,,,M,Y,3.13,KG,20180109,,CN,BR,BR,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Cryptorchism;Foetal exposure during pregnancy,143320292,OT,,,143320292,1,20170607,,,,143320292,1,HIV infection
14336554,143365542,2,F,,20180329,20171229,20180331,EXP,,IT-AUROBINDO-AUR-APL-2017-48135,AUROBINDO,,27,YR,,F,Y,,,20180331,,OT,IT,IT,EFAVIRENZ.,End stage renal disease;Pathogen resistance,143365542,OT,,,,,,,,,143365542,1,Antiretroviral therapy
14341582,143415821,1,I,,20171218,20180102,20180102,EXP,,MY-CIPLA LTD.-2017MY30224,CIPLA,,,,,,Y,,,20180102,,OT,MY,MY,EFAVIRENZ.,Face oedema;Photosensitivity reaction,143415821,OT,,,,,,,,,143415821,1,Antiretroviral therapy
14341617,143416171,1,I,,20171218,20180102,20180102,EXP,,MY-CIPLA LTD.-2017MY30209,CIPLA,,,,,,Y,,,20180102,,PH,MY,MY,EFAVIRENZ.,Chapped lips;Ocular hyperaemia;Pruritus;Rash maculo-papular;Urinary incontinence,143416171,OT,,,,,,,,,143416171,1,HIV infection
14341768,143417684,4,F,,20180226,20180102,20180312,EXP,GB-FERRINGPH-2017FE05839,GB-LUPIN PHARMACEUTICALS INC.-2017-07582,LUPIN,,,,,M,Y,,,20180312,,CN,GB,GB,EFAVIRENZ.,Drug interaction;Renal impairment,143417684,OT,,,,,,,,,143417684,1,Cardiovascular event prophylaxis
14341843,143418431,1,I,20160818,20171207,20180102,20180102,EXP,,BR-MYLANLABS-2017M1081635,MYLAN,,27,YR,,F,Y,,,20180102,,OT,BR,BR,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Maternal exposure during pregnancy;Stillbirth,143418431,OT,,,,,,,,,143418431,1,Product used for unknown indication
14344034,143440341,1,I,,20171221,20180102,20180102,EXP,,GB-SHIRE-GB201735739,SHIRE,,,,,,Y,,,20171228,,MD,GB,GB,EFAVIRENZ.,Drug interaction;Renal impairment,143440341,OT,,,,,,,,,143440341,1,Inflammatory bowel disease
14344346,143443461,1,I,,20171218,20180102,20180102,EXP,,GB-MYLANLABS-2017M1083674,MYLAN,"WYNBERG E, WILLIAMS E, TUDOR-WILLIAMS G, LYALL H, FOSTER C.. DISCONTINUATION OF EFAVIRENZ IN PAEDIATRIC PATIENTS: WHY DO CHILDREN SWITCH?.. CLIN DRUG INVESTIG.. 2017;1-8",,,,,Y,,,20180102,,MD,GB,GB,EFAVIRENZ.,Disturbance in attention;Enuresis;Fatigue;Gynaecomastia;Headache;Hypercholesterolaemia;Mood altered;Psychotic disorder;Sleep disorder;Stevens-Johnson syndrome;Virologic failure,143443461,OT,,,,,,,,,143443461,1,Product used for unknown indication
14345648,143456482,2,F,,20180119,20180103,20180203,EXP,,GB-AUROBINDO-AUR-APL-2017-48622,AUROBINDO,,,,,,Y,,,20180203,,CN,GB,GB,EFAVIRENZ.,Drug interaction;Renal impairment,143456482,OT,,,,,,,,,143456482,1,Cardiovascular event prophylaxis
14347590,143475904,4,F,,20180115,20180103,20180312,EXP,GB-EMA-DD-20171218-DEEPAKEVHPDD-092620,GB-SHIRE-GB201735217,SHIRE,,,,,,Y,,,20180310,,CN,GB,GB,EFAVIRENZ.,Drug interaction;Renal impairment,143475904,OT,,,,,,,,,143475904,1,Crohn's disease
14352961,143529611,1,I,20150608,20171220,20180104,20180104,EXP,,FR-MYLANLABS-2018M1000485,MYLAN,,,,,M,Y,3,KG,20180104,,MD,FR,FR,SUSTIVA,Foetal exposure during pregnancy;Foetal growth restriction;Low birth weight baby;Small for dates baby,143529611,OT,,,143529611,5,20150608,20150608,,,143529611,1,HIV infection
14355025,143550254,4,F,,20180224,20180105,20180312,EXP,,GB-AUROBINDO-AUR-APL-2018-000089,AUROBINDO,,85,YR,,M,Y,,,20180311,,CN,GB,GB,EFAVIRENZ.,Drug interaction;Renal impairment,143550254,OT,,,,,,,,,143550254,1,Cardiovascular event prophylaxis
14361836,143618361,1,I,,20171226,20180108,20180108,EXP,,US-CIPLA LTD.-2017US30878,CIPLA,,,,,,Y,,,20180108,,OT,US,US,EFAVIRENZ.,Exposure during pregnancy;Premature delivery,143618361,OT,,,,,,,,,143618361,1,HIV infection
14361837,143618371,1,I,,20171226,20180108,20180108,EXP,,US-CIPLA LTD.-2017US30879,CIPLA,,,,,,Y,,,20180108,,OT,US,US,EFAVIRENZ.,Exposure during pregnancy;Premature delivery,143618371,OT,,,,,,,,,143618371,1,HIV infection
14362160,143621601,1,I,,20171226,20180108,20180108,EXP,,US-CIPLA LTD.-2017US30911,CIPLA,,,,,,Y,,,20180108,,OT,US,US,EFAVIRENZ.,Foetal exposure during pregnancy;Premature baby,143621601,OT,,,,,,,,,,,
14362161,143621611,1,I,,20171226,20180108,20180108,EXP,,US-CIPLA LTD.-2017US30912,CIPLA,,,,,,Y,,,20180108,,OT,US,US,EFAVIRENZ.,Foetal exposure during pregnancy;Premature baby,143621611,OT,,,,,,,,,,,
14363782,143637822,2,F,201404,20180108,20180108,20180122,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-098391,BRISTOL MYERS SQUIBB,,27,YR,,F,Y,,,20180122,,CN,IT,IT,EFAVIRENZ.,Drug resistance;End stage renal disease;Prescribed overdose;Treatment noncompliance;Viral mutation identified;Virologic failure,143637822,OT,,,,,,,,,143637822,1,HIV infection
14364072,143640721,1,I,,20180103,20180108,20180108,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2018001286,VIIV,"ALVES BM, SIQUEIRA JD, GARRIDO MM, BOTELHO OM, PRELLWITZ IM, RIBEIRO SR. ALVES BM, SIQUEIRA JD, GARRIDO MM, BOTELHO OM, PRELLWITZ IM, RIBEIRO SR.ET.AL CHARACTERIZATION OF HIV-1 NEAR FULL-LENGTH PROVIRAL GENOME QUASISPECIES FROM PATIENTS WITH UNDETECTABLE VIRAL LOAD UNDERGOING FIRST-LINE HAART THERAPY. VIRUSES. 2017;9(12): ARTICLE NUMBER 392.",,,,,Y,,,20180108,,OT,BR,BR,EFAVIRENZ.,Drug resistance;Viral mutation identified,143640721,OT,,,,,,,,,143640721,1,Antiretroviral therapy
14364074,143640741,1,I,,20180103,20180108,20180108,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2018001284,VIIV,"ALVES BM, SIQUEIRA JD, GARRIDO MM, BOTELHO OM, PRELLWITZ IM, RIBEIRO SR.ET.AL CHARACTERIZATION OF HIV-1 NEAR FULL-LENGTH PROVIRAL GENOME QUASISPECIES FROM PATIENTS WITH UNDETECTABLE VIRAL LOAD UNDERGOING FIRST-LINE HAART THERAPY. VIRUSES. 2017;9(12): ARTICLE NUMBER 392.",,,,,Y,,,20180108,,OT,BR,BR,EFAVIRENZ.,Drug resistance;Viral mutation identified,143640741,OT,,,,,,,,,143640741,1,Antiretroviral therapy
14364076,143640761,1,I,,20180103,20180108,20180108,EXP,,BR-GLAXOSMITHKLINE-BR2018001286,GLAXOSMITHKLINE,"ALVES BM, SIQUEIRA JD, GARRIDO MM, BOTELHO OM, PRELLWITZ IM, RIBEIRO SR. ALVES BM, SIQUEIRA JD, GARRIDO MM, BOTELHO OM, PRELLWITZ IM, RIBEIRO SR.ET.AL CHARACTERIZATION OF HIV-1 NEAR FULL-LENGTH PROVIRAL GENOME QUASISPECIES FROM PATIENTS WITH UNDETECTABLE VIRAL LOAD UNDERGOING FIRST-LINE HAART THERAPY. VIRUSES. 2017;9(12): ARTICLE NUMBER 392.",,,,,Y,,,20180108,,OT,BR,BR,EFAVIRENZ.,Drug resistance;Viral mutation identified,143640761,OT,,,,,,,,,143640761,1,Antiretroviral therapy
14364079,143640791,1,I,,20180103,20180108,20180108,EXP,,BR-GLAXOSMITHKLINE-BR2018001284,GLAXOSMITHKLINE,"ALVES BM, SIQUEIRA JD, GARRIDO MM, BOTELHO OM, PRELLWITZ IM, RIBEIRO SR.ET.AL CHARACTERIZATION OF HIV-1 NEAR FULL-LENGTH PROVIRAL GENOME QUASISPECIES FROM PATIENTS WITH UNDETECTABLE VIRAL LOAD UNDERGOING FIRST-LINE HAART THERAPY. VIRUSES. 2017;9(12): ARTICLE NUMBER 392.",,,,,Y,,,20180108,,OT,BR,BR,EFAVIRENZ.,Drug resistance;Viral mutation identified,143640791,OT,,,,,,,,,143640791,1,Antiretroviral therapy
14364280,143642801,1,I,,20180103,20180108,20180108,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2018001287,VIIV,"ALVES BM, SIQUEIRA JD, GARRIDO MM, BOTELHO OM, PRELLWITZ IM, RIBEIRO SR.ET.AL CHARACTERIZATION OF HIV-1 NEAR FULL-LENGTH PROVIRAL GENOME QUASISPECIES FROM PATIENTS WITH UNDETECTABLE VIRAL LOAD UNDERGOING FIRST-LINE HAART THERAPY. VIRUSES. 2017;9(12): ARTICLE NUMBER 392.",,,,,Y,,,20180108,,OT,BR,BR,EFAVIRENZ.,Drug resistance;Viral mutation identified,143642801,OT,,,,,,,,,143642801,1,Antiretroviral therapy
14364282,143642821,1,I,,20180103,20180108,20180108,EXP,,BR-GLAXOSMITHKLINE-BR2018001287,GLAXOSMITHKLINE,"ALVES BM, SIQUEIRA JD, GARRIDO MM, BOTELHO OM, PRELLWITZ IM, RIBEIRO SR.ET.AL CHARACTERIZATION OF HIV-1 NEAR FULL-LENGTH PROVIRAL GENOME QUASISPECIES FROM PATIENTS WITH UNDETECTABLE VIRAL LOAD UNDERGOING FIRST-LINE HAART THERAPY. VIRUSES. 2017;9(12): ARTICLE NUMBER 392.",,,,,Y,,,20180108,,OT,BR,BR,EFAVIRENZ.,Drug resistance;Viral mutation identified,143642821,OT,,,,,,,,,143642821,1,Antiretroviral therapy
14364385,143643851,1,I,,20180103,20180108,20180108,EXP,,BR-GLAXOSMITHKLINE-BR2018001289,GLAXOSMITHKLINE,"ALVES BM, SIQUEIRA JD, GARRIDO MM, BOTELHO OM, PRELLWITZ IM, RIBEIRO SR.ET.AL CHARACTERIZATION OF HIV-1 NEAR FULL-LENGTH PROVIRAL GENOME QUASISPECIES FROM PATIENTS WITH UNDETECTABLE VIRAL LOAD UNDERGOING FIRST-LINE HAART THERAPY. VIRUSES. 2017;9(12): ARTICLE NUMBER 392.",,,,,Y,,,20180108,,OT,BR,BR,EFAVIRENZ.,Drug resistance;Viral mutation identified,143643851,OT,,,,,,,,,143643851,1,Antiretroviral therapy
14364386,143643861,1,I,,20180103,20180108,20180108,EXP,,BR-GLAXOSMITHKLINE-BR2018001290,GLAXOSMITHKLINE,"ALVES BM, SIQUEIRA JD, GARRIDO MM, BOTELHO OM, PRELLWITZ IM, RIBEIRO SR. ALVES BM, SIQUEIRA JD, GARRIDO MM, BOTELHO OM, PRELLWITZ IM, RIBEIRO SR.ET.AL CHARACTERIZATION OF HIV-1 NEAR FULL-LENGTH PROVIRAL GENOME QUASISPECIES FROM PATIENTS WITH UNDETECTABLE VIRAL LOAD UNDERGOING FIRST-LINE HAART THERAPY. VIRUSES. 2017;9(12): ARTICLE NUMBER 392.",,,,,Y,,,20180108,,OT,BR,BR,EFAVIRENZ.,Drug resistance;Viral mutation identified,143643861,OT,,,,,,,,,143643861,1,Antiretroviral therapy
14364387,143643871,1,I,,20180103,20180108,20180108,EXP,,BR-GLAXOSMITHKLINE-BR2018001288,GLAXOSMITHKLINE,"ALVES BM, SIQUEIRA JD, GARRIDO MM, BOTELHO OM, PRELLWITZ IM, RIBEIRO SR.ET.AL CHARACTERIZATION OF HIV-1 NEAR FULL-LENGTH PROVIRAL GENOME QUASISPECIES FROM PATIENTS WITH UNDETECTABLE VIRAL LOAD UNDERGOING FIRST-LINE HAART THERAPY. VIRUSES. 2017;9(12): ARTICLE NUMBER 392.",,,,,Y,,,20180108,,OT,BR,BR,EFAVIRENZ.,Drug resistance;Viral mutation identified;Virologic failure,143643871,OT,,,,,,,,,143643871,1,Antiretroviral therapy
14364388,143643881,1,I,,20180103,20180108,20180108,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2018001289,VIIV,"ALVES BM, SIQUEIRA JD, GARRIDO MM, BOTELHO OM, PRELLWITZ IM, RIBEIRO SR.ET.AL CHARACTERIZATION OF HIV-1 NEAR FULL-LENGTH PROVIRAL GENOME QUASISPECIES FROM PATIENTS WITH UNDETECTABLE VIRAL LOAD UNDERGOING FIRST-LINE HAART THERAPY. VIRUSES. 2017;9(12): ARTICLE NUMBER 392.",,,,,Y,,,20180108,,OT,BR,BR,EFAVIRENZ.,Drug resistance;Viral mutation identified,143643881,OT,,,,,,,,,143643881,1,Antiretroviral therapy
14364389,143643891,1,I,,20180103,20180108,20180108,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2018001290,VIIV,"ALVES BM, SIQUEIRA JD, GARRIDO MM, BOTELHO OM, PRELLWITZ IM, RIBEIRO SR. ALVES BM, SIQUEIRA JD, GARRIDO MM, BOTELHO OM, PRELLWITZ IM, RIBEIRO SR.ET.AL CHARACTERIZATION OF HIV-1 NEAR FULL-LENGTH PROVIRAL GENOME QUASISPECIES FROM PATIENTS WITH UNDETECTABLE VIRAL LOAD UNDERGOING FIRST-LINE HAART THERAPY. VIRUSES. 2017;9(12): ARTICLE NUMBER 392.",,,,,Y,,,20180108,,OT,BR,BR,EFAVIRENZ.,Drug resistance;Viral mutation identified,143643891,OT,,,,,,,,,143643891,1,Antiretroviral therapy
14364390,143643901,1,I,,20180103,20180108,20180108,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2018001288,VIIV,"ALVES BM, SIQUEIRA JD, GARRIDO MM, BOTELHO OM, PRELLWITZ IM, RIBEIRO SR.ET.AL CHARACTERIZATION OF HIV-1 NEAR FULL-LENGTH PROVIRAL GENOME QUASISPECIES FROM PATIENTS WITH UNDETECTABLE VIRAL LOAD UNDERGOING FIRST-LINE HAART THERAPY. VIRUSES. 2017;9(12): ARTICLE NUMBER 392.",,,,,Y,,,20180108,,OT,BR,BR,EFAVIRENZ.,Drug resistance;Viral mutation identified;Virologic failure,143643901,OT,,,,,,,,,143643901,1,Antiretroviral therapy
14364413,143644131,1,I,,20180103,20180108,20180108,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2018001291,VIIV,"ALVES BM, SIQUEIRA JD, GARRIDO MM, BOTELHO OM, PRELLWITZ IM, RIBEIRO SR.ET.AL CHARACTERIZATION OF HIV-1 NEAR FULL-LENGTH PROVIRAL GENOME QUASISPECIES FROM PATIENTS WITH UNDETECTABLE VIRAL LOAD UNDERGOING FIRST-LINE HAART THERAPY. VIRUSES. 2017;9(12): ARTICLE NUMBER 392.",,,,,Y,,,20180108,,OT,BR,BR,EFAVIRENZ.,Drug resistance;Viral mutation identified,143644131,OT,,,,,,,,,143644131,1,Antiretroviral therapy
14364414,143644141,1,I,,20180103,20180108,20180108,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2018001294,VIIV,"ALVES BM, SIQUEIRA JD, GARRIDO MM, BOTELHO OM, PRELLWITZ IM, RIBEIRO SR. CHARACTERIZATION OF HIV-1 NEAR FULL-LENGTH PROVIRAL GENOME QUASISPECIES FROM PATIENTS WITH UNDETECTABLE VIRAL LOAD UNDERGOING FIRST-LINE HAART THERAPY. VIRUSES. 2017;9(12): ARTICLE NUMBER 392.",,,,,Y,,,20180108,,OT,BR,BR,EFAVIRENZ.,Drug resistance;Viral mutation identified,143644141,OT,,,,,,,,,143644141,1,Antiretroviral therapy
14364415,143644151,1,I,,20180103,20180108,20180108,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2018001292,VIIV,"ALVES BM, SIQUEIRA JD, GARRIDO MM, BOTELHO OM, PRELLWITZ IM, RIBEIRO SR.ET.AL CHARACTERIZATION OF HIV-1 NEAR FULL-LENGTH PROVIRAL GENOME QUASISPECIES FROM PATIENTS WITH UNDETECTABLE VIRAL LOAD UNDERGOING FIRST-LINE HAART THERAPY. VIRUSES. 2017;9(12): ARTICLE NUMBER 392.",,,,,Y,,,20180108,,OT,BR,BR,EFAVIRENZ.,Drug resistance;Viral mutation identified,143644151,OT,,,,,,,,,143644151,1,Antiretroviral therapy
14364416,143644161,1,I,,20180103,20180108,20180108,EXP,,BR-GLAXOSMITHKLINE-BR2018001291,GLAXOSMITHKLINE,"ALVES BM, SIQUEIRA JD, GARRIDO MM, BOTELHO OM, PRELLWITZ IM, RIBEIRO SR.ET.AL CHARACTERIZATION OF HIV-1 NEAR FULL-LENGTH PROVIRAL GENOME QUASISPECIES FROM PATIENTS WITH UNDETECTABLE VIRAL LOAD UNDERGOING FIRST-LINE HAART THERAPY. VIRUSES. 2017;9(12): ARTICLE NUMBER 392.",,,,,Y,,,20180108,,OT,BR,BR,EFAVIRENZ.,Drug resistance;Viral mutation identified,143644161,OT,,,,,,,,,143644161,1,Antiretroviral therapy
14364417,143644171,1,I,,20180103,20180108,20180108,EXP,,BR-GLAXOSMITHKLINE-BR2018001294,GLAXOSMITHKLINE,"ALVES BM, SIQUEIRA JD, GARRIDO MM, BOTELHO OM, PRELLWITZ IM, RIBEIRO SR. CHARACTERIZATION OF HIV-1 NEAR FULL-LENGTH PROVIRAL GENOME QUASISPECIES FROM PATIENTS WITH UNDETECTABLE VIRAL LOAD UNDERGOING FIRST-LINE HAART THERAPY. VIRUSES. 2017;9(12): ARTICLE NUMBER 392.",,,,,Y,,,20180108,,OT,BR,BR,EFAVIRENZ.,Drug resistance;Viral mutation identified,143644171,OT,,,,,,,,,143644171,1,Antiretroviral therapy
14364419,143644191,1,I,,20180103,20180108,20180108,EXP,,BR-GLAXOSMITHKLINE-BR2018001292,GLAXOSMITHKLINE,"ALVES BM, SIQUEIRA JD, GARRIDO MM, BOTELHO OM, PRELLWITZ IM, RIBEIRO SR.ET.AL CHARACTERIZATION OF HIV-1 NEAR FULL-LENGTH PROVIRAL GENOME QUASISPECIES FROM PATIENTS WITH UNDETECTABLE VIRAL LOAD UNDERGOING FIRST-LINE HAART THERAPY. VIRUSES. 2017;9(12): ARTICLE NUMBER 392.",,,,,Y,,,20180108,,OT,BR,BR,EFAVIRENZ.,Drug resistance;Viral mutation identified,143644191,OT,,,,,,,,,143644191,1,Antiretroviral therapy
14364453,143644531,1,I,,20180103,20180108,20180108,EXP,,BR-GLAXOSMITHKLINE-BR2018001295,GLAXOSMITHKLINE,"ALVES BM, SIQUEIRA JD, GARRIDO MM, BOTELHO OM, PRELLWITZ IM, RIBEIRO SR.ET.AL CHARACTERIZATION OF HIV-1 NEAR FULL-LENGTH PROVIRAL GENOME QUASISPECIES FROM PATIENTS WITH UNDETECTABLE VIRAL LOAD UNDERGOING FIRST-LINE HAART THERAPY. VIRUSES. 2017;9(12): ARTICLE NUMBER 392.",,,,,Y,,,20180108,,OT,BR,BR,EFAVIRENZ.,Drug resistance;Viral mutation identified,143644531,OT,,,,,,,,,143644531,1,Antiretroviral therapy
14364454,143644541,1,I,,20180103,20180108,20180108,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2018001295,VIIV,"ALVES BM, SIQUEIRA JD, GARRIDO MM, BOTELHO OM, PRELLWITZ IM, RIBEIRO SR.ET.AL CHARACTERIZATION OF HIV-1 NEAR FULL-LENGTH PROVIRAL GENOME QUASISPECIES FROM PATIENTS WITH UNDETECTABLE VIRAL LOAD UNDERGOING FIRST-LINE HAART THERAPY. VIRUSES. 2017;9(12): ARTICLE NUMBER 392.",,,,,Y,,,20180108,,OT,BR,BR,EFAVIRENZ.,Drug resistance;Viral mutation identified,143644541,OT,,,,,,,,,143644541,1,Antiretroviral therapy
14366042,143660421,1,I,,20171226,20180109,20180109,EXP,,US-CIPLA LTD.-2017US30747,CIPLA,,,,,,Y,,,20180109,,OT,US,US,EFAVIRENZ.,Foetal exposure during pregnancy;Premature baby,143660421,OT,,,,,,,,,,,
14366099,143660991,1,I,,20171226,20180109,20180109,EXP,,US-CIPLA LTD.-2017US30750,CIPLA,,,,,,Y,,,20180109,,OT,US,US,EFAVIRENZ.,Exposure during pregnancy;Premature delivery,143660991,OT,,,,,,,,,143660991,1,HIV infection
14366162,143661621,1,I,,20180104,20180109,20180109,EXP,,CA-009507513-1801CAN001991,MERCK,,,,,,Y,,,20180109,,OT,CA,CA,EFAVIRENZ.,Acute kidney injury;Alanine aminotransferase increased;Anaemia;Aspartate aminotransferase increased;Blood bilirubin increased;Cerebral ischaemia;Cystitis noninfective;Drug interaction;Febrile neutropenia;Haematuria;Infection;Myalgia;Pulmonary embolism;Seizure;Thrombosis;Tumour lysis syndrome;Vomiting,143661621,OT,,,,,,,,,143661621,1,HIV infection
14366163,143661631,1,I,,20171226,20180109,20180109,EXP,,US-CIPLA LTD.-2017US30820,CIPLA,,,,,,Y,,,20180109,,OT,US,US,EFAVIRENZ.,Exposure during pregnancy;Foetal death,143661631,OT,,,,,,,,,143661631,1,HIV infection
14366190,143661901,1,I,,20171226,20180109,20180109,EXP,,US-CIPLA LTD.-2017US30822,CIPLA,,,,,,Y,,,20180109,,OT,US,US,EFAVIRENZ.,Exposure during pregnancy;Foetal death,143661901,OT,,,,,,,,,143661901,1,HIV infection
14366194,143661941,1,I,,20171226,20180109,20180109,EXP,,US-CIPLA LTD.-2017US30821,CIPLA,,,,,,Y,,,20180109,,OT,US,US,EFAVIRENZ.,Exposure during pregnancy;Foetal death,143661941,OT,,,,,,,,,143661941,1,HIV infection
14366655,143666551,1,I,,20171226,20180109,20180109,EXP,,US-CIPLA LTD.-2017US30827,CIPLA,,,,,,Y,,,20180109,,OT,US,US,EFAVIRENZ.,Exposure during pregnancy;Foetal death,143666551,OT,,,,,,,,,143666551,1,HIV infection
14366656,143666561,1,I,,20171226,20180109,20180109,EXP,,US-CIPLA LTD.-2017US30823,CIPLA,,,,,,Y,,,20180109,,OT,US,US,EFAVIRENZ.,Exposure during pregnancy;Foetal death,143666561,OT,,,,,,,,,143666561,1,HIV infection
14366657,143666571,1,I,,20171226,20180109,20180109,EXP,,US-CIPLA LTD.-2017US30831,CIPLA,,,,,,Y,,,20180109,,OT,US,US,EFAVIRENZ.,Exposure during pregnancy;Premature delivery,143666571,OT,,,,,,,,,143666571,1,HIV infection
14366658,143666581,1,I,,20171226,20180109,20180109,EXP,,US-CIPLA LTD.-2017US30833,CIPLA,,,,,,Y,,,20180109,,OT,US,US,EFAVIRENZ.,Exposure during pregnancy;Premature delivery,143666581,OT,,,,,,,,,143666581,1,HIV infection
14366659,143666591,1,I,,20171226,20180109,20180109,EXP,,US-CIPLA LTD.-2017US30824,CIPLA,,,,,,Y,,,20180109,,OT,US,US,EFAVIRENZ.,Exposure during pregnancy;Foetal death,143666591,OT,,,,,,,,,143666591,1,HIV infection
14366660,143666601,1,I,,20171226,20180109,20180109,EXP,,US-CIPLA LTD.-2017US30825,CIPLA,,,,,,Y,,,20180109,,OT,US,US,EFAVIRENZ.,Exposure during pregnancy;Foetal death,143666601,OT,,,,,,,,,143666601,1,HIV infection
14366661,143666611,1,I,,20171226,20180109,20180109,EXP,,US-CIPLA LTD.-2017US30826,CIPLA,,,,,,Y,,,20180109,,OT,US,US,EFAVIRENZ.,Exposure during pregnancy;Foetal death,143666611,OT,,,,,,,,,143666611,1,HIV infection
14366662,143666621,1,I,,20171226,20180109,20180109,EXP,,US-CIPLA LTD.-2017US30832,CIPLA,,,,,,Y,,,20180109,,OT,US,US,EFAVIRENZ.,Exposure during pregnancy;Premature delivery,143666621,OT,,,,,,,,,143666621,1,HIV infection
14367046,143670461,1,I,,20171226,20180109,20180109,EXP,,US-CIPLA LTD.-2017US30861,CIPLA,,,,,,Y,,,20180109,,OT,US,US,EFAVIRENZ.,Foetal exposure during pregnancy;Premature baby,143670461,OT,,,,,,,,,,,
14367047,143670471,1,I,,20171226,20180109,20180109,EXP,,US-CIPLA LTD.-2017US30857,CIPLA,,,,,,Y,,,20180109,,OT,US,US,EFAVIRENZ.,Death neonatal;Foetal exposure during pregnancy,143670471,DE,,,,,,,,,,,
14367048,143670481,1,I,,20171226,20180109,20180109,EXP,,US-CIPLA LTD.-2017US30859,CIPLA,,,,,,Y,,,20180109,,OT,US,US,EFAVIRENZ.,Death neonatal;Foetal exposure during pregnancy,143670481,DE,,,,,,,,,,,
14367049,143670491,1,I,,20171226,20180109,20180109,EXP,,US-CIPLA LTD.-2017US30860,CIPLA,,,,,,Y,,,20180109,,OT,US,US,EFAVIRENZ.,Foetal exposure during pregnancy;Premature baby,143670491,OT,,,,,,,,,,,
14367050,143670501,1,I,,20171226,20180109,20180109,EXP,,US-CIPLA LTD.-2017US30862,CIPLA,,,,,,Y,,,20180109,,OT,US,US,EFAVIRENZ.,Foetal exposure during pregnancy;Premature baby,143670501,OT,,,,,,,,,,,
14367051,143670511,1,I,,20171226,20180109,20180109,EXP,,US-CIPLA LTD.-2017US30858,CIPLA,,,,,,Y,,,20180109,,OT,US,US,EFAVIRENZ.,Death neonatal;Foetal exposure during pregnancy,143670511,DE,,,,,,,,,,,
14367906,143679062,2,F,2015,20180227,20180109,20180313,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-118541,BRISTOL MYERS SQUIBB,,56,YR,,M,Y,57,KG,20180313,,MD,FR,FR,SUSTIVA,General physical condition abnormal;Hypermetabolism;Pulmonary mass;Virologic failure,143679062,HO,,,143679062,5,20151117,,,,143679062,1,HIV infection
14370236,143702361,1,I,,20180108,20180110,20180110,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-001324,BRISTOL MYERS SQUIBB,,,,,,Y,,,20180110,,PH,US,US,SUSTIVA,Product storage error,,,,,,,,,,,143702361,1,Product used for unknown indication
14376262,143762622,2,F,20160216,20180118,20180111,20180125,EXP,,US-EXELIXIS-XL18418011920,EXELIXIS,,63,YR,,M,Y,112.7,KG,20180125,,MD,US,US,EFAVIRENZ W/EMTRICITABINE/TENOFOVIR,Cerebrovascular accident,143762622,HO,,,143762622,1,20140121,,,,143762622,1,Kaposi's sarcoma
14379460,143794601,1,I,,20180108,20180112,20180112,EXP,,US-HETERO CORPORATE-HET2018US00019,HETERO,"ONYEMA OGBUAGU, RITCHE HAO, MICHAEL VIRATA, MERCEDITAS S. VILLANUEVA MARICAR MALINIS. EFFICACY OF AN 8-WEEK COURSE OF SOFOSBUVIR AND LEDIPASVIR FOR THE TREATMENT OF HCV INFECTION IN SELECTED HIV-INFECTED PATIENTS.. F1000RESEARCH. 2017;6:620:1-8",,,,M,Y,,,20180112,,OT,US,US,EFAVIRENZ.,Acute kidney injury,143794601,OT,,,,,,,,,143794601,1,HIV infection
14379754,143797541,1,I,20171107,20180102,20180112,20180112,EXP,,GB-AUROBINDO-AUR-APL-2018-001814,AUROBINDO,,47,YR,,F,Y,,,20180112,,MD,GB,GB,EFAVIRENZ.,Acute hepatic failure;Product substitution issue,143797541,HO,,,143797541,1,20170501,20171216,,,143797541,1,HIV infection
14380117,143801171,1,I,,20180102,20180112,20180112,EXP,,CA-AUROBINDO-AUR-APL-2018-001060,AUROBINDO,,32,YR,,M,Y,,,20180112,,PH,CA,CA,AURO-EFAVIRENZ TABLETS,Depression;Mood altered;Neurotoxicity;Suicide attempt,143801171,LT,,,,,,,,,143801171,1,Antiretroviral therapy
14385936,143859361,1,I,20141118,20180105,20180115,20180115,EXP,,GB-GILEAD-2018-0314495,GILEAD,,,,,F,Y,80.1,KG,20180115,,OT,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Hip arthroplasty,143859361,HO,,,,,,,,,143859361,1,Antiretroviral therapy
14393108,143931081,1,I,,20171229,20180116,20180116,EXP,,FR-GLAXOSMITHKLINE-FR2017202986,GLAXOSMITHKLINE,,54,YR,,M,Y,,,20180116,,MD,FR,FR,SUSTIVA,Virologic failure,143931081,OT,,,143931081,1,20021113,20140402,,,143931081,1,HIV infection
14393109,143931091,1,I,,20171229,20180116,20180116,EXP,,FR-VIIV HEALTHCARE LIMITED-FR2017202986,VIIV,,54,YR,,M,Y,,,20180116,,MD,FR,FR,SUSTIVA,Virologic failure,143931091,OT,,,143931091,1,20021113,20140402,,,143931091,1,HIV infection
14395520,143955201,1,I,,20180108,20180116,20180116,EXP,,BR-GILEAD-2018-0315135,GILEAD,"ALVES B,SIQUEIRA J, GARRIDO M, BOTELHO O, PRELLWITZ I, RIBEIRO S, SOARES E, SOARES M. CHARACTERIZATION OF HIV-1 NEAR FULL-LENGTH PROVIRAL GENOME QUASISPECIES FROM PATIENTS WITH UNDETECTABLE VIRAL LOAD UNDERGOING FIRST-LINE HAART THERAPY. VIRUSES. 2017;9 (12):UNK",,,A,,Y,,,20180116,,MD,BR,BR,EFAVIRENZ.,Drug ineffective;Drug resistance;Gene mutation identification test positive;Viral load increased,143955201,OT,,,,,,,,,143955201,1,HIV infection
14398198,143981981,1,I,,20180110,20180116,20180116,EXP,,US-VIIV HEALTHCARE LIMITED-US2018GSK007224,VIIV,"GILL MM, HOFFMAN HJ, NDATIMANA D, MUGWANEZA P, GUAY L, NDAYISABA GF ET AL.. 24-MONTH HIV-FREE SURVIVAL AMONG INFANTS BORN TO HIV-POSITIVE WOMEN ENROLLED IN OPTION B+ PROGRAM IN KIGALI, RWANDA. MEDICINE. 2017;96 (51):E9445",,,C,,Y,,,20180116,,MD,US,US,EFAVIRENZ.,Anal atresia;Foetal exposure during pregnancy,143981981,OT,,,,,,,,,143981981,1,HIV infection
14398199,143981991,1,I,,20180110,20180116,20180116,EXP,,US-VIIV HEALTHCARE LIMITED-US2018GSK007225,VIIV,"GILL MM, HOFFMAN HJ, NDATIMANA D, MUGWANEZA P, GUAY L, NDAYISABA GF ET AL.. 24-MONTH HIV-FREE SURVIVAL AMONG INFANTS BORN TO HIV-POSITIVE WOMEN ENROLLED IN OPTION B+ PROGRAM IN KIGALI, RWANDA. MEDICINE. 2017;96 (51):E9445",,,C,,Y,,,20180116,,MD,US,US,EFAVIRENZ.,Foetal exposure during pregnancy;Heart disease congenital,143981991,CA,,,,,,,,,143981991,1,HIV infection
14398200,143982001,1,I,,20180110,20180116,20180116,EXP,,US-VIIV HEALTHCARE LIMITED-US2018GSK007221,VIIV,"GILL MM, HOFFMAN HJ, NDATIMANA D, MUGWANEZA P, GUAY L, NDAYISABA GF ET AL.. 24-MONTH HIV-FREE SURVIVAL AMONG INFANTS BORN TO HIV-POSITIVE WOMEN ENROLLED IN OPTION B+ PROGRAM IN KIGALI, RWANDA. MEDICINE. 2017;96 (51):E9445",,,C,,Y,,,20180116,,MD,US,US,EFAVIRENZ.,Anaemia;Foetal exposure during pregnancy,143982001,DE,,,,,,,,,143982001,1,HIV infection
14398201,143982011,1,I,,20180110,20180116,20180116,EXP,,US-VIIV HEALTHCARE LIMITED-US2018GSK007222,VIIV,"GILL MM, HOFFMAN HJ, NDATIMANA D, MUGWANEZA P, GUAY L, NDAYISABA GF ET AL.. 24-MONTH HIV-FREE SURVIVAL AMONG INFANTS BORN TO HIV-POSITIVE WOMEN ENROLLED IN OPTION B+ PROGRAM IN KIGALI, RWANDA. MEDICINE. 2017;96 (51):E9445",,,C,,Y,,,20180116,,MD,US,US,EFAVIRENZ.,Foetal exposure during pregnancy;Pyrexia,143982011,DE,,,,,,,,,143982011,1,HIV infection
14398202,143982021,1,I,,20180110,20180116,20180116,EXP,,US-VIIV HEALTHCARE LIMITED-US2018GSK007198,VIIV,"GILL MM, HOFFMAN HJ, NDATIMANA D, MUGWANEZA P, GUAY L, NDAYISABA GF ET AL.. 24-MONTH HIV-FREE SURVIVAL AMONG INFANTS BORN TO HIV-POSITIVE WOMEN ENROLLED IN OPTION B+ PROGRAM IN KIGALI, RWANDA. MEDICINE. 2017;96 (51):E9445",,,C,,Y,,,20180116,,MD,US,US,EFAVIRENZ.,Diarrhoea;Foetal exposure during pregnancy,143982021,DE,,,,,,,,,143982021,1,HIV infection
14398203,143982031,1,I,,20180110,20180116,20180116,EXP,,US-VIIV HEALTHCARE LIMITED-US2018GSK007220,VIIV,"GILL MM, HOFFMAN HJ, NDATIMANA D, MUGWANEZA P, GUAY L, NDAYISABA GF ET AL.. 24-MONTH HIV-FREE SURVIVAL AMONG INFANTS BORN TO HIV-POSITIVE WOMEN ENROLLED IN OPTION B+ PROGRAM IN KIGALI, RWANDA. MEDICINE. 2017;96 (51):E9445",,,C,,Y,,,20180116,,MD,US,US,EFAVIRENZ.,Foetal exposure during pregnancy;Tuberculosis,143982031,DE,,,,,,,,,143982031,1,HIV infection
14398204,143982041,1,I,,20180110,20180116,20180116,EXP,,US-VIIV HEALTHCARE LIMITED-US2018GSK007223,VIIV,"GILL MM, HOFFMAN HJ, NDATIMANA D, MUGWANEZA P, GUAY L, NDAYISABA GF ET AL.. 24-MONTH HIV-FREE SURVIVAL AMONG INFANTS BORN TO HIV-POSITIVE WOMEN ENROLLED IN OPTION B+ PROGRAM IN KIGALI, RWANDA. MEDICINE. 2017;96 (51):E9445",,,C,,Y,,,20180116,,MD,US,US,EFAVIRENZ.,Foetal exposure during pregnancy;Malnutrition,143982041,DE,,,,,,,,,143982041,1,HIV infection
14398205,143982051,1,I,,20180110,20180116,20180116,EXP,,US-GLAXOSMITHKLINE-US2018GSK007225,GLAXOSMITHKLINE,"GILL MM, HOFFMAN HJ, NDATIMANA D, MUGWANEZA P, GUAY L, NDAYISABA GF ET AL.. 24-MONTH HIV-FREE SURVIVAL AMONG INFANTS BORN TO HIV-POSITIVE WOMEN ENROLLED IN OPTION B+ PROGRAM IN KIGALI, RWANDA. MEDICINE. 2017;96 (51):E9445",,,C,,Y,,,20180116,,MD,US,US,EFAVIRENZ.,Foetal exposure during pregnancy;Heart disease congenital,143982051,OT,,,,,,,,,143982051,1,HIV infection
14398206,143982061,1,I,,20180110,20180116,20180116,EXP,,US-GLAXOSMITHKLINE-US2018GSK007224,GLAXOSMITHKLINE,"GILL MM, HOFFMAN HJ, NDATIMANA D, MUGWANEZA P, GUAY L, NDAYISABA GF ET AL.. 24-MONTH HIV-FREE SURVIVAL AMONG INFANTS BORN TO HIV-POSITIVE WOMEN ENROLLED IN OPTION B+ PROGRAM IN KIGALI, RWANDA. MEDICINE. 2017;96 (51):E9445",,,C,,Y,,,20180116,,MD,US,US,EFAVIRENZ.,Anal atresia;Foetal exposure during pregnancy,143982061,OT,,,,,,,,,143982061,1,HIV infection
14398207,143982071,1,I,,20180110,20180116,20180116,EXP,,US-GLAXOSMITHKLINE-US2018GSK007221,GLAXOSMITHKLINE,"GILL MM, HOFFMAN HJ, NDATIMANA D, MUGWANEZA P, GUAY L, NDAYISABA GF ET AL.. 24-MONTH HIV-FREE SURVIVAL AMONG INFANTS BORN TO HIV-POSITIVE WOMEN ENROLLED IN OPTION B+ PROGRAM IN KIGALI, RWANDA. MEDICINE. 2017;96 (51):E9445",,,C,,Y,,,20180116,,MD,US,US,EFAVIRENZ.,Anaemia;Foetal exposure during pregnancy,143982071,DE,,,,,,,,,143982071,1,HIV infection
14398208,143982081,1,I,,20180110,20180116,20180116,EXP,,US-GLAXOSMITHKLINE-US2018GSK007222,GLAXOSMITHKLINE,"GILL MM, HOFFMAN HJ, NDATIMANA D, MUGWANEZA P, GUAY L, NDAYISABA GF ET AL.. 24-MONTH HIV-FREE SURVIVAL AMONG INFANTS BORN TO HIV-POSITIVE WOMEN ENROLLED IN OPTION B+ PROGRAM IN KIGALI, RWANDA. MEDICINE. 2017;96 (51):E9445",,,C,,Y,,,20180116,,MD,US,US,EFAVIRENZ.,Foetal exposure during pregnancy;Pyrexia,143982081,DE,,,,,,,,,143982081,1,HIV infection
14398209,143982091,1,I,,20180110,20180116,20180116,EXP,,US-GLAXOSMITHKLINE-US2018GSK007220,GLAXOSMITHKLINE,"GILL MM, HOFFMAN HJ, NDATIMANA D, MUGWANEZA P, GUAY L, NDAYISABA GF ET AL.. 24-MONTH HIV-FREE SURVIVAL AMONG INFANTS BORN TO HIV-POSITIVE WOMEN ENROLLED IN OPTION B+ PROGRAM IN KIGALI, RWANDA. MEDICINE. 2017;96 (51):E9445",,,C,,Y,,,20180116,,MD,US,US,EFAVIRENZ.,Foetal exposure during pregnancy;Tuberculosis,143982091,DE,,,,,,,,,143982091,1,HIV infection
14398210,143982101,1,I,,20180110,20180116,20180116,EXP,,US-GLAXOSMITHKLINE-US2018GSK007198,GLAXOSMITHKLINE,"GILL MM, HOFFMAN HJ, NDATIMANA D, MUGWANEZA P, GUAY L, NDAYISABA GF ET AL.. 24-MONTH HIV-FREE SURVIVAL AMONG INFANTS BORN TO HIV-POSITIVE WOMEN ENROLLED IN OPTION B+ PROGRAM IN KIGALI, RWANDA. MEDICINE. 2017;96 (51):E9445",,,C,,Y,,,20180116,,MD,US,US,EFAVIRENZ.,Diarrhoea;Foetal exposure during pregnancy,143982101,DE,,,,,,,,,143982101,1,HIV infection
14398211,143982111,1,I,,20180110,20180116,20180116,EXP,,US-GLAXOSMITHKLINE-US2018GSK007223,GLAXOSMITHKLINE,"GILL MM, HOFFMAN HJ, NDATIMANA D, MUGWANEZA P, GUAY L, NDAYISABA GF ET AL.. 24-MONTH HIV-FREE SURVIVAL AMONG INFANTS BORN TO HIV-POSITIVE WOMEN ENROLLED IN OPTION B+ PROGRAM IN KIGALI, RWANDA. MEDICINE. 2017;96 (51):E9445",,,C,,Y,,,20180116,,MD,US,US,EFAVIRENZ.,Foetal exposure during pregnancy;Malnutrition,143982111,DE,,,,,,,,,143982111,1,HIV infection
14398398,143983981,1,I,,20180104,20180116,20180116,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-001661,BRISTOL MYERS SQUIBB,,,,A,M,Y,,,20180116,,OT,US,US,EFAVIRENZ.,Acute kidney injury,143983981,OT,,,,,,,,,143983981,1,HIV infection
14398660,143986605,5,F,20171107,20180316,20180117,20180330,EXP,GB-MHRA-EYC 00171403,GB-LUPIN PHARMACEUTICALS INC.-2018-00076,LUPIN,,47,YR,,F,Y,,,20180330,,CN,GB,GB,EFAVIRENZ.,Acute hepatic failure;Product substitution issue,143986605,HO,,,143986605,1,20170501,20171216,,,143986605,1,HIV infection
14401450,144014501,1,I,20180115,,20180115,20180115,DIR,,,FDA-CTU,,68,YR,,M,N,,,20180115,N,PH,US,US,SUSTIVA,Lymphadenopathy,,,144014501,HP,,,,,,,,,
14402110,144021101,1,I,,20180104,20180117,20180117,EXP,,US-MYLANLABS-2018M1002223,MYLAN,"OGBUAGU O, HAO R, VIRATA M, VILLANUEVA MS, MALINIS M. EFFICACY OF AN 8-WEEK COURSE OF SOFOSBUVIR AND LEDIPASVIR FOR THE TREATMENT OF HCV INFECTION IN SELECTED HIV-INFECTED PATIENTS. F1000RES 2017;6:620.",,,A,M,Y,,,20180117,,OT,US,US,EFAVIRENZ.,Acute kidney injury,144021101,OT,,,,,,,,,144021101,1,HIV infection
14404464,144044641,1,I,,20171211,20180117,20180117,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-120521,BRISTOL MYERS SQUIBB,,30,YR,,F,Y,,,20180117,,MD,FR,FR,SUSTIVA,Maternal exposure during pregnancy;Product use issue;Tuberculosis,144044641,OT,,,144044641,1,20051201,,,,144044641,1,Antiretroviral therapy
14404833,144048332,2,F,,20180213,20180118,20180227,EXP,,PE-SUN PHARMACEUTICAL INDUSTRIES LTD-2017R1-148238,RANBAXY,"MONTALVO R, TICONA E, NAVINCOPA M, GARCIA Y, CHAVEZ G, CHAVEZ V, ET AL. RECURRENT DIARRHEA DUE TO CYSTOISOPORA BELLI IN HIV/AIDS PATIENTS RECEIVING HAART. REVISTA PERU MED EXP SALUD PUBL. 2013;30(2):326-330",34,YR,,M,Y,,,20180227,,OT,PE,PE,Didanosine/Lamivudine/Efavirenz,Diarrhoea;Drug ineffective;Isosporiasis,144048332,DE,,,,,,,,,144048332,1,Prophylaxis
14404835,144048352,2,F,,20180213,20180118,20180227,EXP,,PE-SUN PHARMACEUTICAL INDUSTRIES LTD-2017R1-148236,RANBAXY,"MONTALVO R, TICONA E, NAVINCOPA M, GARCIA Y, CHAVEZ G, CHAVEZ V, ET AL. RECURRENT DIARRHEA DUE TO CYSTOISOPORA BELLI IN HIV/AIDS PATIENTS RECEIVING HAART. REVISTA PERU MED EXP SALUD PUBL. 2013;30(2):326-330",39,YR,,M,Y,,,20180227,,OT,PE,PE,EFAVIRENZ.,Diarrhoea;Drug ineffective;Isosporiasis,144048352,DE,,,,,,,,,144048352,1,Prophylaxis
14404837,144048372,2,F,,20180213,20180118,20180227,EXP,,PE-SUN PHARMACEUTICAL INDUSTRIES LTD-2017R1-148235,RANBAXY,"MONTALVO R, TICONA E, NAVINCOPA M, GARCIA Y, CHAVEZ G, CHAVEZ V, ET AL. RECURRENT DIARRHEA DUE TO CYSTOISOPORA BELLI IN HIV/AIDS PATIENTS RECEIVING HAART. REVISTA PERU MED EXP SALUD PUBL. 2013;30(2):326-330",32,YR,,M,Y,,,20180227,,OT,PE,PE,EFAVIRENZ.,Diarrhoea;Drug ineffective;Isosporiasis,144048372,DE,,,,,,,,,144048372,1,Prophylaxis
14408319,144083191,1,I,,20180104,20180118,20180118,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-003535,BRISTOL MYERS SQUIBB,,,,A,M,Y,,,20180118,,OT,US,US,EFAVIRENZ.,Fatigue;Influenza,,,,,,,,,,,144083191,1,HIV infection
14408320,144083201,1,I,,20180104,20180118,20180118,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-003534,BRISTOL MYERS SQUIBB,,,,A,M,Y,,,20180118,,OT,US,US,EFAVIRENZ.,Abdominal pain;Diarrhoea,,,,,,,,,,,144083201,1,HIV infection
14408321,144083211,1,I,,20180104,20180118,20180118,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-003536,BRISTOL MYERS SQUIBB,,,,A,M,Y,,,20180118,,OT,US,US,EFAVIRENZ.,Chronic obstructive pulmonary disease,,,,,,,,,,,144083211,1,HIV infection
14409362,144093621,1,I,,20180108,20180119,20180119,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2018007433,VIIV,"ALVES B,SIQUEIRA J, GARRIDO M, BOTELHO O, PRELLWITZ I, RIBEIRO S, SOARES E, SOARES M. CHARACTERIZATION OF HIV-1 NEAR FULL-LENGTH PROVIRAL GENOME QUASISPECIES FROM PATIENTS WITH UNDETECTABLE VIRAL LOAD UNDERGOING FIRST-LINE HAART THERAPY. VIRUSES. 2017;9 (12):UNK",,,A,,Y,,,20180118,,MD,BR,BR,EFAVIRENZ.,Drug ineffective;Drug resistance;Gene mutation identification test positive;Viral load increased,144093621,OT,,,,,,,,,144093621,1,HIV infection
14409365,144093651,1,I,,20180115,20180119,20180119,EXP,,GB-VIIV HEALTHCARE LIMITED-GB2018GSK008901,VIIV,"COLUMPSI P, BHAGANI S. LAMIVUDINE RESISTANT HBV REACTIVATION IN AN HIV-INFECTED PATIENT FOLLOWING IMMUNE SUPPRESSION POST-RENAL TRANSPLANTATION. 16TH EUROPEAN AIDS CONFERENCE - EUROPEAN AIDS CLINICAL SOCIETY (EACS)  :  ():. 2017",56,YR,,M,Y,,,20180118,,OT,GB,GB,EFAVIRENZ.,Pathogen resistance;Viral mutation identified,144093651,OT,,,,,,,,,144093651,1,HIV infection
14409370,144093701,1,I,,20180108,20180119,20180119,EXP,,BR-GLAXOSMITHKLINE-BR2018007433,GLAXOSMITHKLINE,"ALVES B,SIQUEIRA J, GARRIDO M, BOTELHO O, PRELLWITZ I, RIBEIRO S, SOARES E, SOARES M. CHARACTERIZATION OF HIV-1 NEAR FULL-LENGTH PROVIRAL GENOME QUASISPECIES FROM PATIENTS WITH UNDETECTABLE VIRAL LOAD UNDERGOING FIRST-LINE HAART THERAPY. VIRUSES. 2017;9 (12):UNK",,,A,,Y,,,20180118,,MD,BR,BR,EFAVIRENZ.,Drug ineffective;Drug resistance;Gene mutation identification test positive;Viral load increased,144093701,OT,,,,,,,,,144093701,1,HIV infection
14409378,144093781,1,I,,20180115,20180119,20180119,EXP,,GB-GLAXOSMITHKLINE-GB2018GSK008901,GLAXOSMITHKLINE,"COLUMPSI P, BHAGANI S. LAMIVUDINE RESISTANT HBV REACTIVATION IN AN HIV-INFECTED PATIENT FOLLOWING IMMUNE SUPPRESSION POST-RENAL TRANSPLANTATION. 16TH EUROPEAN AIDS CONFERENCE - EUROPEAN AIDS CLINICAL SOCIETY (EACS)  :  ():. 2017",56,YR,,M,Y,,,20180118,,OT,GB,GB,EFAVIRENZ.,Pathogen resistance;Viral mutation identified,144093781,OT,,,,,,,,,144093781,1,HIV infection
14413250,144132501,1,I,,20180117,20180119,20180119,EXP,,GA-VIIV HEALTHCARE LIMITED-GA2018008936,VIIV,"BIVIGOU-MBOUMBA B, AMOUGOU-ATSAMA M, ZOA-ASSOUMOU S, KAMDEM HM, NZENGUI-NZENGUI GF, NDOJYI-MBIGUINO A, ET AL. HEPATITIS B INFECTION AMONG HIV INFECTED INDIVIDUALS IN GABON: OCCULT HEPATITIS B ENHANCES HBV DNA PREVALENCE. PLOS ONE. 2018;13(1):E0190592. DOI: 10.1371/JOURNAL.PONE.0190592.",53,YR,,M,Y,,,20180119,,OT,GA,GA,EFAVIRENZ.,Drug resistance;Viral mutation identified,144132501,OT,,,,,,,,,144132501,1,HIV infection
14413251,144132511,1,I,,20180117,20180119,20180119,EXP,,GA-VIIV HEALTHCARE LIMITED-GA2018008935,VIIV,"BIVIGOU-MBOUMBA B, AMOUGOU-ATSAMA M, ZOA-ASSOUMOU S, KAMDEM HM, NZENGUI-NZENGUI GF, NDOJYI-MBIGUINO A, ET AL. HEPATITIS B INFECTION AMONG HIV INFECTED INDIVIDUALS IN GABON: OCCULT HEPATITIS B ENHANCES HBV DNA PREVALENCE. PLOS ONE. 2018;13(1):E0190592. DOI: 10.1371/JOURNAL.PONE.0190592.",49,YR,,M,Y,,,20180119,,OT,GA,GA,EFAVIRENZ.,Drug resistance;Viral mutation identified,144132511,OT,,,,,,,,,144132511,1,HIV infection
14413271,144132711,1,I,,20180117,20180119,20180119,EXP,,GA-GLAXOSMITHKLINE-GA2018008936,GLAXOSMITHKLINE,"BIVIGOU-MBOUMBA B, AMOUGOU-ATSAMA M, ZOA-ASSOUMOU S, KAMDEM HM, NZENGUI-NZENGUI GF, NDOJYI-MBIGUINO A, ET AL. HEPATITIS B INFECTION AMONG HIV INFECTED INDIVIDUALS IN GABON: OCCULT HEPATITIS B ENHANCES HBV DNA PREVALENCE. PLOS ONE. 2018;13(1):E0190592. DOI: 10.1371/JOURNAL.PONE.0190592.",53,YR,,M,Y,,,20180119,,OT,GA,GA,EFAVIRENZ.,Drug resistance;Viral mutation identified,144132711,OT,,,,,,,,,144132711,1,HIV infection
14413272,144132721,1,I,,20180117,20180119,20180119,EXP,,GA-GLAXOSMITHKLINE-GA2018008935,GLAXOSMITHKLINE,"BIVIGOU-MBOUMBA B, AMOUGOU-ATSAMA M, ZOA-ASSOUMOU S, KAMDEM HM, NZENGUI-NZENGUI GF, NDOJYI-MBIGUINO A, ET AL. HEPATITIS B INFECTION AMONG HIV INFECTED INDIVIDUALS IN GABON: OCCULT HEPATITIS B ENHANCES HBV DNA PREVALENCE. PLOS ONE. 2018;13(1):E0190592. DOI: 10.1371/JOURNAL.PONE.0190592.",49,YR,,M,Y,,,20180119,,OT,GA,GA,EFAVIRENZ.,Drug resistance;Viral mutation identified,144132721,OT,,,,,,,,,144132721,1,HIV infection
14415884,144158843,3,F,20171107,20180227,20180122,20180313,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-001016,BRISTOL MYERS SQUIBB,,47,YR,,F,Y,,,20180313,,MD,GB,GB,EFAVIRENZ.,Acute hepatic failure;Product substitution issue,144158843,HO,,,144158843,1,20170501,20170516,,,144158843,1,HIV infection
14418134,144181342,2,F,,20180117,20180122,20180129,EXP,,GA-VIIV HEALTHCARE LIMITED-GA2018008940,VIIV,"BIVIGOU-MBOUMBA B, AMOUGOU-ATSAMA M, ZOA-ASSOUMOU S, KAMDEM HM, NZENGUI-NZENGUI GF, NDOJYI-MBIGUINO A, ET AL. HEPATITIS B INFECTION AMONG HIV INFECTED INDIVIDUALS IN GABON: OCCULT HEPATITIS B ENHANCES HBV DNA PREVALENCE. PLOS ONE. 2018;13(1):E0190592. DOI: 10.1371/JOURNAL.PONE.0190592.",46,YR,,F,Y,,,20180129,,OT,GA,GA,EFAVIRENZ.,Drug resistance;Viral mutation identified,144181342,OT,,,,,,,,,144181342,1,HIV infection
14420283,144202831,1,I,,20170130,20180122,20180122,PER,,US-ROCHE-1887978,ROCHE,"FORBES R, DEMERS A, CONCEPCION B, MOORE D, SCHAEFER H AND SHAFFER D. A2 TO B BLOOD TYPE INCOMPATIBLE DECEASED DONOR KIDNEY TRANSPLANTATION IN A RECIPIENT INFECTED WITH THE HUMAN IMMUNODEFICIENCY VIRUS: A CASE REPORT.. TRANSPLANTATION PROCEEDINGS 2017 JAN 01;49 (1):206-209.",39,YR,,M,Y,,,20180122,,OT,US,US,EFAVIRENZ.,Cytomegalovirus infection;Gastrointestinal disorder,,,,,,,,,,,144202831,1,Immunosuppression
14431924,144319241,1,I,,20180109,20180124,20180124,EXP,,US-JAZZ-2018-US-001480,JAZZ,,,,,M,Y,,,20180124,,MD,US,US,EFAVIRENZ.,Spermatic cord disorder;Testicular disorder,144319241,OT,,,144319241,1,201507,201507,,,144319241,1,Narcolepsy
14447342,144473421,1,I,,20180122,20180126,20180126,EXP,,VN-GLAXOSMITHKLINE-VN2018012671,GLAXOSMITHKLINE,"THANH NT, VINH LD, LIEM NT, SHIKUMA C, DAY JN, THWAITES G ET AL. CLINICAL FEATURES OF THREE PATIENTS WITH PARADOXICAL IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME ASSOCIATED WITH TALAROMYCES MARNEFFEI INFECTION. MEDICAL MYCOLOGY CASE REPORTS. 2018;19():33-37. DOI: 10.1016/J.MMCR.2016.12.005.",31,YR,,F,Y,,,20180126,,OT,VN,VN,EFAVIRENZ.,Immune reconstitution inflammatory syndrome,144473421,HO,,,,,,,,,144473421,1,Antiretroviral therapy
14447344,144473441,1,I,,20180122,20180126,20180126,EXP,,VN-VIIV HEALTHCARE LIMITED-VN2018012671,VIIV,"THANH NT, VINH LD, LIEM NT, SHIKUMA C, DAY JN, THWAITES G ET AL. CLINICAL FEATURES OF THREE PATIENTS WITH PARADOXICAL IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME ASSOCIATED WITH TALAROMYCES MARNEFFEI INFECTION. MEDICAL MYCOLOGY CASE REPORTS. 2018;19():33-37. DOI: 10.1016/J.MMCR.2016.12.005.",31,YR,,F,Y,,,20180126,,OT,VN,VN,EFAVIRENZ.,Immune reconstitution inflammatory syndrome,144473441,HO,,,,,,,,,144473441,1,Antiretroviral therapy
14450746,144507461,1,I,,20180124,20180129,20180129,EXP,,US-GILEAD-2018-0317999,GILEAD,,62,YR,A,M,Y,,,20180129,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Death,144507461,DE,,,,,,,,,144507461,1,HIV infection
14453674,144536741,1,I,,20180117,20180129,20180129,EXP,,GA-GLAXOSMITHKLINE-GA2018008940,GLAXOSMITHKLINE,"BIVIGOU-MBOUMBA B, AMOUGOU-ATSAMA M, ZOA-ASSOUMOU S, KAMDEM HM, NZENGUI-NZENGUI GF, NDOJYI-MBIGUINO A, ET AL. HEPATITIS B INFECTION AMONG HIV INFECTED INDIVIDUALS IN GABON: OCCULT HEPATITIS B ENHANCES HBV DNA PREVALENCE. PLOS ONE. 2018;13(1):E0190592. DOI: 10.1371/JOURNAL.PONE.0190592.",46,YR,,F,Y,,,20180129,,OT,GA,GA,EFAVIRENZ.,Drug resistance;Viral mutation identified,144536741,OT,,,,,,,,,144536741,1,HIV infection
14454904,144549041,1,I,20170309,20170912,20180129,20180129,EXP,,UG-GILEAD-2017-0293742,GILEAD,,28,YR,A,F,Y,,,20180129,,OT,UG,UG,EFAVIRENZ.,Maternal exposure during pregnancy;Stillbirth,144549041,OT,,,144549041,1,20170309,20170313,,,144549041,1,HIV infection
14457122,144571222,2,F,,20180301,20180130,20180316,EXP,,US-AUROBINDO-AUR-APL-2018-003659,AUROBINDO,,,,,,Y,,,20180316,,OT,US,US,EFAVIRENZ.,Acute kidney injury,144571222,OT,,,,,,,,,144571222,1,HIV infection
14457277,144572771,1,I,,20180116,20180130,20180130,EXP,,GB-AUROBINDO-AUR-APL-2018-004041,AUROBINDO,,,,,,Y,,,20180130,,CN,GB,GB,EFAVIRENZ.,Lip and/or oral cavity cancer,144572771,OT,,,,,,,,,144572771,1,Antiretroviral therapy
14459633,144596331,1,I,,20180124,20180130,20180130,EXP,,US-GILEAD-2018-0317976,GILEAD,,31,YR,A,M,Y,,,20180130,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Impaired work ability;Surgery,144596331,OT,,,,,,,,,144596331,1,HIV infection
14460481,144604812,2,F,20170309,20180302,20180130,20180305,EXP,,UG-GLAXOSMITHKLINE-UG2017203170,GLAXOSMITHKLINE,,28,YR,,F,Y,,,20180305,,OT,UG,UG,EFAVIRENZ.,Drug-induced liver injury;Maternal exposure during pregnancy;Stillbirth,144604812,OT,,,144604812,1,20170309,20170313,,,144604812,2,HIV infection
14460922,144609222,2,F,20170309,20180302,20180130,20180305,EXP,,UG-VIIV HEALTHCARE LIMITED-UG2017203170,VIIV,,28,YR,,F,Y,,,20180305,,OT,UG,UG,EFAVIRENZ.,Drug-induced liver injury;Maternal exposure during pregnancy;Stillbirth,144609222,OT,,,144609222,1,20170309,20170313,,,144609222,2,HIV infection
14462981,144629812,2,F,,20180228,20180130,20180305,EXP,,GB-ALLERGAN-1771124US,ALLERGAN,,85,YR,,M,Y,,,20180305,,MD,GB,GB,EFAVIRENZ.,Drug interaction;Renal impairment,144629812,OT,,,,,,,,,144629812,1,Inflammatory bowel disease
14463771,144637713,3,F,,20180201,20180130,20180212,EXP,,UG-HETERO-HET2018UG00056,HETERO,,,,,M,Y,2.5,KG,20180212,,OT,UG,UG,EFAVIRENZ.,Congenital knee dislocation;Congenital limb hyperextension;Congenital syphilis;Cushingoid;Developmental hip dysplasia;Foetal exposure during pregnancy;Hair texture abnormal;Micrognathia;Skull malformation;Talipes;Wrist deformity,144637713,CA,,,144637713,1,20171206,20180112,,,144637713,1,HIV infection
14470002,144700021,1,I,2015,20180117,20180131,20180131,EXP,,GB-MYLANLABS-2018M1005555,MYLAN,,40,YR,,F,Y,,,20180122,,CN,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Drug prescribing error;Ectopic pregnancy with contraceptive device;Immunodeficiency;Internal haemorrhage;Labelled drug-drug interaction medication error;Maternal exposure during pregnancy;Pregnancy with implant contraceptive;Unintended pregnancy,144700021,LT,,,144700021,3,20130901,20160107,,,144700021,1,HIV infection
14474245,144742452,2,F,,20180209,20180201,20180219,EXP,,GB-009507513-1801GBR008170,MERCK,"COLUMPSI P, BHAGANI S. LAMIVUDINE RESISTANT HBV REACTIVATION IN AN HIV-INFECTED PATIENT FOLLOWING IMMUNE SUPPRESSION POST-RENAL TRANSPLANTATION.. 16TH EUROPEAN AIDS CONFERENCE - EUROPEAN AIDS CLINICAL SOCIETY (EACS). 2017",56,YR,,M,Y,,,20180219,,OT,GB,GB,EFAVIRENZ.,Pathogen resistance;Viral mutation identified,144742452,OT,,,,,,,,,144742452,1,HIV infection
14474585,144745852,2,F,20171107,20180131,20180201,20180212,EXP,GB-MHRA-EYC 00171403,GB-MYLANLABS-2018M1006020,MYLAN,,47,YR,,F,Y,,,20180207,,MD,GB,GB,EFAVIRENZ.,Acute hepatic failure;Product substitution issue,144745852,HO,,,144745852,1,20170501,20171216,,,144745852,1,HIV infection
14475173,144751733,3,F,,20180316,20180201,20180328,EXP,,IE-ASTELLAS-2018US005582,ASTELLAS,,37,YR,,F,Y,,,20180328,,OT,GB,IE,EFAVIRENZ.,Cushingoid;Leukopenia;Off label use;Skin atrophy,144751733,OT,,,,,,,,,144751733,1,Sarcoidosis
14475832,144758321,1,I,,20180126,20180201,20180201,EXP,,SG-ABBVIE-18S-141-2239299-00,ABBVIE,"YOUNG B, YEO T, LIM H, ET AL. PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY WITH IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME (PML-IRIS): TWO CASE REPORTS OF SUCCESSFUL TREATMENT WITH MEFLOQUINE AND A REVIEW OF THE LITERATURE. ANNALS ACADEMY OF MEDICINE SG. ANNALS ACADEMY OF MEDICINE. 2012 DEC;VOLUME 41 ISSUE 12:620-624.",39,YR,,M,Y,,,20180201,,OT,COUNTRY NOT SPECIFIED,SG,EFAVIRENZ.,Immune reconstitution inflammatory syndrome;Progressive multifocal leukoencephalopathy,144758321,OT,,,,,,,,,144758321,1,HIV infection
14476706,144767061,1,I,20150608,20180117,20180201,20180201,EXP,,PHHY2018FR016372,SANDOZ,,,,N,M,Y,2.64,KG,20180201,,OT,FR,FR,SUSTIVA,Foetal exposure during pregnancy;Foetal growth restriction;Low birth weight baby;Small for dates baby,144767061,OT,,,144767061,4,20150608,20150608,,,144767061,1,Foetal exposure during pregnancy
14479122,144791221,1,I,,20180119,20180202,20180202,EXP,,ET-CIPLA LTD.-2018ET03089,CIPLA,"BIRLIE B, BRAEKERS R, AWOKE T, KASIM A, SHKEDY Z. MULTI-STATE MODELS FOR THE ANALYSIS OF TIME-TO-TREATMENT MODIFICATION AMONG HIV PATIENTS UNDER HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN SOUTHWEST ETHIOPIA. BMC INFECTIOUS DISEASES. 2017;17 (453):1 TO 13",,,,,Y,,,20180202,,OT,ET,ET,EFAVIRENZ.,Treatment failure,144791221,OT,,,,,,,,,144791221,1,HIV infection
14481960,144819602,2,F,,20180301,20180202,20180302,EXP,,ZA-GILEAD-2018-0317596,GILEAD,"SPRINGER PE, SLOGROVE AL, LAUGHTON B, BETTINGER JA, SAUNDERS HH, MOLTENO CD, KRUGER M. NEURODEVELOPMENTAL OUTCOME OF HIV-EXPOSED BUT UNINFECTED INFANTS IN THE MOTHER AND INFANTS HEALTH STUDY, CAPE TOWN, SOUTH AFRICA. TROPICAL MEDICINE AND INTERNATIONAL HEALTH. 2018;23:69-78 DOI:10.1111/TMI.13006",,,I,,Y,,,20180302,,OT,ZA,ZA,EFAVIRENZ.,Foetal exposure during pregnancy;Macrocephaly,144819602,OT,,,,,,,,,144819602,1,HIV infection
14482018,144820182,2,F,,20180301,20180202,20180302,EXP,,ZA-GILEAD-2018-0318424,GILEAD,"SPRINGER PE, SLOGROVE AL, LAUGHTON B, BETTINGER JA, SAUNDERS HH, MOLTENO CD, KRUGER M. NEURODEVELOPMENTAL OUTCOME OF HIV-EXPOSED BUT UNINFECTED INFANTS IN THE MOTHER AND INFANTS HEALTH STUDY, CAPE TOWN, SOUTH AFRICA. TROPICAL MEDICINE AND INTERNATIONAL HEALTH. 2018;23:69-78 DOI:10.1111/TMI.13006",,,I,,Y,,,20180302,,OT,ZA,ZA,EFAVIRENZ.,Foetal exposure during pregnancy;Macrocephaly,144820182,OT,,,,,,,,,144820182,1,HIV infection
14482673,144826731,1,I,,20180129,20180203,20180203,EXP,,US-HETERO CORPORATE-HET2018US00083,HETERO,"MU A, SHEIN TT, JAYACHANDRAN P, PAUL S. IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN PATIENTS WITH AIDS AND DISSEMINATED COCCIDIOIDOMYCOSIS: A CASE SERIES AND REVIEW OF THE LITERATURE. J-INT-ASSOC-PROVID-AIDS-CARE. 2017;16(6):540-545",37,YR,,F,Y,,,20180203,,OT,US,US,Efavirenz+Emtricitabine+Tenofovir,Coccidioidomycosis;Condition aggravated;Immune reconstitution inflammatory syndrome,144826731,OT,,,,,,,,,144826731,1,HIV infection
14484952,144849521,1,I,20171207,20180130,20180205,20180205,EXP,,CN-GLAXOSMITHKLINE-CN2018GSK018141,GLAXOSMITHKLINE,,58,YR,,M,Y,52,KG,20180205,,OT,CN,CN,STOCRIN (EFAVIRENZ),Decreased appetite;Drug-induced liver injury;Hepatic function abnormal,144849521,HO,,,144849521,1,20170711,20171207,,,144849521,1,Viral infection
14485393,144853933,3,F,20180112,20180201,20180205,20180216,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-010659,BRISTOL MYERS SQUIBB,,21,YR,,F,Y,,,20180216,,OT,UG,UG,EFAVIRENZ.,Maternal exposure during pregnancy;Premature delivery;Product use issue,144853933,OT,,,144853933,1,20171206,,,,144853933,1,HIV infection
14485443,144854432,2,F,20180112,20180201,20180205,20180216,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-006758,BRISTOL MYERS SQUIBB,,0,DY,,M,Y,2.5,KG,20180216,,OT,UG,UG,EFAVIRENZ.,Congenital knee deformity;Connective tissue disorder;Cushingoid;Developmental hip dysplasia;Elbow deformity;Foetal exposure during pregnancy;Hair texture abnormal;Micrognathia;Premature baby;Skull malformation;Talipes;Wrist deformity,144854432,OT,,,144854432,1,20171206,20180112,,,144854432,1,Product used for unknown indication
14489861,144898612,2,F,,20180127,20180206,20180209,EXP,,UG-CIPLA LTD.-2018UG02611,CIPLA,,,,,,Y,,,20180209,,OT,UG,UG,EFAVIRENZ.,Congenital knee deformity;Congenital limb hyperextension;Developmental hip dysplasia;Foetal exposure during pregnancy;Premature baby;Skull malformation;Talipes;Wrist deformity,144898612,OT,,,,,,,,,144898612,1,HIV infection
14489873,144898731,1,I,,20180130,20180206,20180206,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-008858,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20180206,,CN,US,US,SUSTIVA,Nasopharyngitis,,,,,,,,,,,144898731,1,Product used for unknown indication
14489887,144898872,2,F,20180112,20180127,20180206,20180209,EXP,,UG-CIPLA LTD.-2018UG02610,CIPLA,,,,,,Y,,,20180209,,OT,UG,UG,EFAVIRENZ.,Exposure during pregnancy;Premature delivery,144898872,OT,,,144898872,1,20171206,,,,144898872,1,HIV infection
14491418,144914182,2,F,,20180302,20180206,20180307,EXP,,US-VIIV HEALTHCARE LIMITED-US2018GSK019485,VIIV,,,,,M,Y,,,20180307,,CN,US,US,SUSTIVA,Pain;Spinal operation,144914182,OT,,,144914182,1,20151102,,,,144914182,1,Product used for unknown indication
14491420,144914201,1,I,20171207,20180130,20180206,20180206,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2018GSK018141,VIIV,,58,YR,,M,Y,52,KG,20180206,,OT,CN,CN,STOCRIN (EFAVIRENZ),Decreased appetite;Drug-induced liver injury;Hepatic function abnormal,144914201,HO,,,144914201,1,20170711,20171207,,,144914201,1,Viral infection
14491697,144916971,1,I,201801,20180122,20180206,20180206,EXP,,UG-AUROBINDO-AUR-APL-2018-003995,AUROBINDO,,,,,M,Y,2.5,KG,20180206,,OT,UG,UG,EFAVIRENZ.,Developmental hip dysplasia;Foetal exposure during pregnancy;Limb deformity;Skull malformation;Talipes,144916971,CA,,,144916971,1,20171206,,,,144916971,1,HIV infection
14492178,144921782,2,F,,20180202,20180206,20180217,EXP,,UG-MYLANLABS-2018M1007722,MYLAN,,,,,M,Y,2.5,KG,20180217,,OT,UG,UG,EFAVIRENZ.,Congenital knee dislocation;Developmental hip dysplasia;Foetal exposure during pregnancy;Joint stiffness;Micrognathia;Skull malformation;Talipes;Wrist deformity,144921782,CA,,,144921782,1,20171206,,,,144921782,1,Product used for unknown indication
14494652,144946521,1,I,,20180123,20180206,20180206,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-006996,BRISTOL MYERS SQUIBB,,52,YR,,M,Y,,,20180206,,CN,CA,CA,SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,144946521,OT,,,,,,,,,144946521,1,HIV infection
14494789,144947892,2,F,,20180123,20180206,20180216,EXP,,US-MYLANLABS-2018M1007325,MYLAN,"MU A, SHEIN TT, JAYACHANDRAN P, PAUL S. IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN PATIENTS WITH AIDS AND DISSEMINATED COCCIDIOIDOMYCOSIS: A CASE SERIES AND REVIEW OF THE LITERATURE. J-INT-ASSOC-PROVID-AIDS-CARE 2017;16(6):540-545.",37,YR,,F,Y,,,20180216,,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Coccidioidomycosis;Immune reconstitution inflammatory syndrome;Infection,144947892,OT,,,,,,,,,144947892,1,HIV infection
14495031,144950312,2,F,,20180209,20180206,20180215,EXP,,VN-GLAXOSMITHKLINE-VN2018019506,GLAXOSMITHKLINE,"THAN N, VINH L, LIEM N, SHIKUMA C, DAY J, THWAITES G, LE T. CLINICAL FEATURES OF THREE PATIENTS WITH PARADOXICAL IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME ASSOCIATED WITH TALAROMYCES MARNEFFEI INFECTION. MEDICAL MYCOLOGY CASE REPORTS. 2018;19:33-37",31,YR,,F,Y,,,20180215,,OT,VN,VN,EFAVIRENZ.,Immune reconstitution inflammatory syndrome,144950312,OT,,,144950312,1,2013,,,,144950312,1,HIV infection
14495042,144950422,2,F,,20180209,20180206,20180215,EXP,,VN-VIIV HEALTHCARE LIMITED-VN2018019506,VIIV,"THAN N, VINH L, LIEM N, SHIKUMA C, DAY J, THWAITES G, LE T. CLINICAL FEATURES OF THREE PATIENTS WITH PARADOXICAL IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME ASSOCIATED WITH TALAROMYCES MARNEFFEI INFECTION. MEDICAL MYCOLOGY CASE REPORTS. 2018;19:33-37",31,YR,,F,Y,,,20180215,,OT,VN,VN,EFAVIRENZ.,Immune reconstitution inflammatory syndrome,144950422,OT,,,144950422,1,2013,,,,144950422,1,HIV infection
14495878,144958781,1,I,,20180124,20180207,20180207,EXP,,ZA-CIPLA (EU) LIMITED-2018ZA02656,CIPLA,"SCRIVEN JE, BOTHA FCJ, SCHUTZ C, LALLOO DG, WAINWRIGHT H, MEINTJES G. PARADOXICAL RESPIRATORY FAILURE DUE TO CRYPTOCOCCAL PNEUMONIA AFTER AMPHOTERICIN B TREATMENT FOR HIV-ASSOCIATED CRYPTOCOCCAL MENINGITIS. MEDICAL MYCOLOGY CASE REPORTS. 2018;19:38 TO 40",,,,,Y,,,20180207,,OT,ZA,ZA,EFAVIRENZ.,Anaemia macrocytic;Meningitis cryptococcal;Pneumonia cryptococcal;Respiratory failure,144958781,DE,,,,,,,,,144958781,1,HIV infection
14497708,144977081,1,I,2015,20180129,20180207,20180207,EXP,,VN-VIIV HEALTHCARE LIMITED-VN2018020373,VIIV,"THAN N, VINH L, LIEM N, SHIKUMA C, DAY J, THWAITES G, LE T.. CLINICAL FEATURES OF THREE PATIENTS WITH PARADOXICAL IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME ASSOCIATED WITH TALAROMYCES MARNEFFEI INFECTION.. MEDICAL MYCOLOGY CASE REPORTS.. 2018;19:33-37",25,YR,,F,Y,,,20180207,,OT,VN,VN,EFAVIRENZ.,Immune reconstitution inflammatory syndrome;Immune reconstitution inflammatory syndrome associated tuberculosis,144977081,HO,,,144977081,1,2015,,,,144977081,1,HIV infection
14497710,144977102,2,F,,20180213,20180207,20180222,EXP,,VN-VIIV HEALTHCARE LIMITED-VN2018020377,VIIV,"LE T, THANH N, VINH L, LIEM N, SHIKUMA C, DAY J, THWAITES G. CLINICAL FEATURES OF THREE PATIENTS WITH PARADOXICAL IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME ASSOCIATED WITH TALAROMYCES MARNEFFEI INFECTION. MEDICAL MYCOLOGY CASE REPORTS. 2018;19:33-37",35,YR,,M,Y,,,20180222,,OT,VN,VN,EFAVIRENZ.,Immune reconstitution inflammatory syndrome,144977102,HO,,,,,,,,,144977102,1,HIV infection
14497847,144978471,1,I,2015,20180129,20180207,20180207,EXP,,VN-GLAXOSMITHKLINE-VN2018020373,GLAXOSMITHKLINE,"THAN N, VINH L, LIEM N, SHIKUMA C, DAY J, THWAITES G, LE T.. CLINICAL FEATURES OF THREE PATIENTS WITH PARADOXICAL IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME ASSOCIATED WITH TALAROMYCES MARNEFFEI INFECTION.. MEDICAL MYCOLOGY CASE REPORTS.. 2018;19:33-37",25,YR,,F,Y,,,20180207,,OT,VN,VN,EFAVIRENZ.,Immune reconstitution inflammatory syndrome;Immune reconstitution inflammatory syndrome associated tuberculosis,144978471,HO,,,144978471,1,2015,,,,144978471,1,HIV infection
14497849,144978492,2,F,,20180213,20180207,20180222,EXP,,VN-GLAXOSMITHKLINE-VN2018020377,GLAXOSMITHKLINE,"LE T, THANH N, VINH L, LIEM N, SHIKUMA C, DAY J, THWAITES G. CLINICAL FEATURES OF THREE PATIENTS WITH PARADOXICAL IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME ASSOCIATED WITH TALAROMYCES MARNEFFEI INFECTION. MEDICAL MYCOLOGY CASE REPORTS. 2018;19:33-37",35,YR,,M,Y,,,20180222,,OT,VN,VN,EFAVIRENZ.,Immune reconstitution inflammatory syndrome,144978492,HO,,,,,,,,,144978492,1,HIV infection
14509357,145093571,1,I,,20180201,20180209,20180209,EXP,,UG-GLAXOSMITHKLINE-UG2018GSK021773,GLAXOSMITHKLINE,,21,YR,,F,Y,,,20180209,,CN,US,UG,EFAVIRENZ.,Exposure during pregnancy;Premature delivery;Syphilis,145093571,OT,,,145093571,1,20171206,,,,145093571,1,HIV infection
14509359,145093591,1,I,20180112,20180203,20180209,20180209,EXP,,UG-GLAXOSMITHKLINE-UG2018GSK021911,GLAXOSMITHKLINE,,0,DY,,M,Y,,,20180209,,CN,US,UG,EFAVIRENZ.,Congenital hair disorder;Cushingoid;Foetal exposure during pregnancy;Low birth weight baby;Micrognathia,145093591,CA,,,145093591,1,20171206,,,,145093591,1,HIV infection
14510208,145102081,1,I,,20180201,20180209,20180209,EXP,,UG-VIIV HEALTHCARE LIMITED-UG2018GSK021773,VIIV,,21,YR,,F,Y,,,20180209,,CN,US,UG,EFAVIRENZ.,Exposure during pregnancy;Premature delivery;Syphilis,145102081,OT,,,145102081,1,20171206,,,,145102081,1,HIV infection
14510210,145102101,1,I,20180112,20180203,20180209,20180209,EXP,,UG-VIIV HEALTHCARE LIMITED-UG2018GSK021911,VIIV,,0,DY,,M,Y,,,20180209,,CN,US,UG,EFAVIRENZ.,Congenital hair disorder;Cushingoid;Foetal exposure during pregnancy;Low birth weight baby;Micrognathia,145102101,CA,,,145102101,1,20171206,,,,145102101,1,HIV infection
14511631,145116311,1,I,20171206,20180122,20180209,20180209,EXP,,UG-GILEAD-2018-0317952,GILEAD,,0,YR,N,M,Y,,,20180209,,OT,UG,UG,EFAVIRENZ.,Autosomal chromosome anomaly;Congenital knee deformity;Developmental hip dysplasia;Dysmorphism;Foetal exposure during pregnancy;Hair texture abnormal;Limb malformation;Micrognathia;Skull malformation;Talipes,145116311,CA,,,145116311,1,20171206,,,,145116311,1,HIV infection
14512063,145120632,2,F,201704,20180206,20180209,20180219,PER,,FR-BIOVERATIV-2018BV000038,BIOVERATIV,,43,YR,,M,Y,62,KG,20180219,,MD,FR,FR,SUSTIVA,Arthralgia;Myalgia,,,,,145120632,1,20170307,,,,145120632,1,Factor VIII deficiency
14514315,145143151,1,I,,20180124,20180209,20180209,EXP,,GB-SHIRE-GB201804914,SHIRE,,,,,,Y,,,20180209,,MD,GB,GB,EFAVIRENZ.,Drug interaction;Renal impairment,145143151,OT,,,,,,,,,145143151,1,Crohn's disease
14519136,145191361,1,I,,20180130,20180212,20180212,EXP,,GB-MYLANLABS-2018M1008448,MYLAN,"COLUMPSI P, BHAGANI S.. LAMIVUDINE RESISTANT HBV REACTIVATION IN AN HIV-INFECTED PATIENT FOLLOWING IMMUNE SUPPRESSION POST-RENAL TRANSPLANTATION.. 16TH EUROPEAN AIDS CONFERENCE - EUROPEAN AIDS CLINICAL SOCIETY (EACS). 2017",56,YR,,M,Y,,,20180212,,OT,GB,GB,EFAVIRENZ.,Pathogen resistance;Viral mutation identified,145191361,OT,,,,,,,,,145191361,1,HIV infection
14519933,145199331,1,I,,20180208,20180212,20180212,EXP,,FR-BAUSCH-BL-2018-003901,BAUSCH AND LOMB,"MAUGE L, PAVIE J, BATISSE D, DARNIGE L. ACQUIRED HEMOPHILIA A RESOLUTION IN A HEPATITIS C VIRUS/HUMAN IMMUNODEFICIENCY VIRUS-COINFECTED PATIENT WITH CURE OF HEPATITIS C BY DIRECT-ACTING ANTIVIRAL AGENTS.. CLINICAL OBSERVATIONS IN HEPATOLOGY. 2018;67(2):794-796.",,,,M,Y,,,20180212,,MD,FR,FR,EFAVIRENZ.,Haematotoxicity,145199331,OT,,,145199331,1,200709,200804,,,145199331,1,Chronic hepatitis C
14525159,145251591,1,I,20171206,20180122,20180213,20180213,EXP,,UG-GLAXOSMITHKLINE-UG2018022996,GLAXOSMITHKLINE,,0,YR,,M,Y,,,20180213,,OT,UG,UG,EFAVIRENZ.,Autosomal chromosome anomaly;Congenital knee deformity;Developmental hip dysplasia;Dysmorphism;Foetal exposure during pregnancy;Hair texture abnormal;Limb malformation;Micrognathia;Skull malformation;Talipes,145251591,CA,,,145251591,1,20171206,,,,145251591,1,HIV infection
14525236,145252361,1,I,20171206,20180122,20180213,20180213,EXP,,UG-VIIV HEALTHCARE LIMITED-UG2018022996,VIIV,,0,YR,,M,Y,,,20180213,,OT,UG,UG,EFAVIRENZ.,Autosomal chromosome anomaly;Congenital knee deformity;Developmental hip dysplasia;Dysmorphism;Foetal exposure during pregnancy;Hair texture abnormal;Limb malformation;Micrognathia;Skull malformation;Talipes,145252361,OT,,,145252361,1,20171206,,,,145252361,1,HIV infection
14527089,145270891,1,I,,20180131,20180213,20180213,EXP,,IE-MYLANLABS-2018M1009569,MYLAN,"BRODERICK C, QUINLAN C, GULMANN C, O^KANE M.. RECALCITRANT CUTANEOUS SARCOIDOSIS, WITH RESPONSE TO DAYLIGHT PHOTODYNAMIC THERAPY.. 2016",37,YR,,F,Y,,,20180213,,OT,IE,IE,EFAVIRENZ.,Cushingoid;Drug ineffective;Leukopenia;Skin atrophy,145270891,OT,,,,,,,,,145270891,1,Sarcoidosis
14529571,145295711,1,I,,20180206,20180214,20180214,EXP,,GA-VIIV HEALTHCARE LIMITED-GA2018024872,VIIV,"NDJOYI-MBIGUINO A, KOMBE A, BIVIGOU-MBOUMBA B, ZOA-ASSOUMOU S, AKOMBI F, NZENGUI F, KAMDEM H, FRANCOIS-SOUQUIERE S.. LOW PREVALENCE OF HCV INFECTION WITH PREDOMINANCE OF GENOTYPE 4 AMONG HIV PATIENTS LIVING IN LIBREVILLE, GABON.. PLOS ONE.. 2018;13:1-12",44,YR,,F,Y,,,20180214,,OT,GA,GA,EFAVIRENZ.,Blood HIV RNA increased;Drug ineffective,145295711,OT,,,,,,,,,145295711,1,HIV infection
14530383,145303831,1,I,20171011,20180130,20180214,20180214,EXP,FR-AFSSAPS-LY20180391,FR-MYLANLABS-2018M1008481,MYLAN,,54,YR,,M,Y,98,KG,20180214,,PH,FR,FR,EFAVIRENZ.,Drug ineffective;No adverse event,145303831,HO,,,145303831,2,201509,,,,145303831,1,HIV infection
14530509,145305091,1,I,,20180206,20180214,20180214,EXP,,GA-GLAXOSMITHKLINE-GA2018024872,GLAXOSMITHKLINE,"NDJOYI-MBIGUINO A, KOMBE A, BIVIGOU-MBOUMBA B, ZOA-ASSOUMOU S, AKOMBI F, NZENGUI F, KAMDEM H, FRANCOIS-SOUQUIERE S.. LOW PREVALENCE OF HCV INFECTION WITH PREDOMINANCE OF GENOTYPE 4 AMONG HIV PATIENTS LIVING IN LIBREVILLE, GABON.. PLOS ONE.. 2018;13:1-12",44,YR,,F,Y,,,20180214,,OT,GA,GA,EFAVIRENZ.,Blood HIV RNA increased;Drug ineffective,145305091,OT,,,,,,,,,145305091,1,HIV infection
14531825,145318251,1,I,20180120,20180123,20180214,20180214,PER,,CA-BIOVERATIV-2018BV000030,BIOVERATIV,,59,YR,,,Y,,,20180214,,CN,CA,CA,EFAVIRENZ.,Haemarthrosis;Hypokinesia;Pain,,,,,145318251,1,20161215,,,,145318251,1,Factor VIII deficiency
14531894,145318942,2,F,20171018,20180201,20180214,20180214,EXP,,PHEH2018US004365,NOVARTIS,,26,YR,,F,Y,33,KG,20180214,,CN,US,US,EFAVIRENZ.,Alanine aminotransferase increased;Anaemia;Aspartate aminotransferase increased;Concomitant disease aggravated;Cough;Failure to thrive;Hepatic enzyme increased;Hypothyroidism;Pyrexia;Vomiting;Weight decreased,145318942,HO,,,145318942,1,20170919,,,,145318942,1,Tuberculosis
14532165,145321651,1,I,20171115,20180206,20180214,20180214,PER,,US-BAYER-2018-025187,BAYER,,87,YR,E,M,Y,51,KG,20180214,,CN,US,US,EFAVIRENZ.,Asthenia;Vomiting,145321651,HO,,,145321651,1,20171103,20171122,,,145321651,2,Product used for unknown indication
14535147,145351471,1,I,,20180201,20180215,20180215,EXP,,UG-MYLANLABS-2018M1009513,MYLAN,,,,,M,Y,2.5,KG,20180215,,OT,UG,UG,EFAVIRENZ.,Developmental hip dysplasia;Foetal exposure during pregnancy;Joint stiffness;Post-traumatic neck syndrome;Skull malformation;Talipes;Wrist deformity,145351471,OT,,,145351471,1,20171206,,,,145351471,1,Product used for unknown indication
14538669,145386691,1,I,,20180213,20180216,20180216,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-014040,BRISTOL MYERS SQUIBB,,,,,,Y,,,20180216,,PH,US,US,SUSTIVA,Medication error,,,,,,,,,,,145386691,1,Product used for unknown indication
14540463,145404631,1,I,20180209,20180210,20180216,20180216,EXP,,BR-GLAXOSMITHKLINE-BR2018GSK026499,GLAXOSMITHKLINE,,31,YR,,F,Y,,,20180216,,CN,US,BR,EFAVIRENZ + LAMIVUDINE + TENOFOVIR,Abortion spontaneous;Exposure during pregnancy,145404631,OT,,,145404631,1,20180103,20180103,,,145404631,1,HIV infection
14541015,145410151,1,I,20180209,20180210,20180216,20180216,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2018GSK026499,VIIV,,31,YR,,F,Y,,,20180216,,CN,US,BR,EFAVIRENZ + LAMIVUDINE + TENOFOVIR,Abortion spontaneous;Exposure during pregnancy,145410151,OT,,,145410151,1,20180103,20180103,,,145410151,1,HIV infection
14541136,145411361,1,I,,20110311,20180216,20180216,EXP,,US-OTSUKA-DJ20111355,OTSUKA,,,,,M,Y,,,20180216,,CN,US,US,SUSTIVA,Drug interaction;T-lymphocyte count decreased;Viral load increased,145411361,OT,,,,,,,,,145411361,1,Product used for unknown indication
14544345,145443452,2,F,20180209,20180219,20180216,20180226,EXP,,BR-ABBVIE-18P-020-2255672-00,ABBVIE,,31,YR,,F,Y,,,20180226,,OT,BR,BR,EFAVIRENZ;LAMIVUDINE;TENOFOVIR,Abortion spontaneous;Exposure during pregnancy,145443452,OT,,,145443452,1,20180103,20180103,,,145443452,1,HIV infection
14544633,145446331,1,I,,20180210,20180217,20180217,EXP,,BR-HETERO CORPORATE-HET2018BR00111,HETERO,,31,YR,,F,Y,,,20180217,,OT,BR,BR,EFAVIRENZ+LAMIVUDINE+TENOFOVIR,Abortion spontaneous;Exposure during pregnancy,145446331,OT,,,145446331,1,20180103,20180103,,,145446331,1,HIV infection
14546665,145466651,1,I,20171018,20180202,20180219,20180219,EXP,,PHHY2018LS020689,NOVARTIS,,26,YR,,F,Y,33,KG,20180219,,CN,LS,LS,EFAVIRENZ.,Anaemia;Condition aggravated;Cough;Failure to thrive;Hepatic enzyme increased;Hypothyroidism;Pyrexia;Vomiting;Weight decreased,145466651,HO,,,145466651,1,20170919,,,,145466651,1,Tuberculosis
14547748,145477481,1,I,20180209,20180209,20180219,20180219,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-014334,BRISTOL MYERS SQUIBB,,31,YR,,F,Y,,,20180219,,OT,BR,BR,EFAVIRENZ + LAMIVUDINE + TENOFOVIR,Abortion spontaneous;Maternal exposure during pregnancy,145477481,OT,,,145477481,1,20180103,20180103,,,145477481,1,HIV infection
14548035,145480351,1,I,20180101,20180205,20180219,20180219,EXP,,LS-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-011495,BRISTOL MYERS SQUIBB,,45,YR,,M,Y,45,KG,20180219,,MD,LS,LS,EFAVIRENZ.,Asthenia;Burning sensation;Dyspnoea;Left ventricular failure;Respiratory failure;Vomiting,145480351,HO,,,145480351,2,20170812,,,,145480351,1,HIV infection
14552465,145524651,1,I,2015,20180205,20180220,20180220,EXP,,US-AUROBINDO-AUR-APL-2018-005890,AUROBINDO,,43,YR,,M,Y,,,20180220,,OT,US,US,EFAVIRENZ.,Cardio-respiratory arrest;Coccidioidomycosis;Hypotension;Immune reconstitution inflammatory syndrome;Night sweats;Pneumonia;Productive cough;Pyrexia,145524651,DE,,,,,,,,,145524651,1,Antiretroviral therapy
14554216,145542161,1,I,2012,20180215,20180220,20180220,EXP,,GB-GILEAD-2018-0321689,GILEAD,,,,,F,Y,,,20180220,,CN,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Arthritis;Knee operation,145542161,OT,,,,,,,,,145542161,1,HIV infection
14554772,145547722,2,F,20171018,20180305,20180220,20180305,EXP,,LS-PFIZER INC-2018068013,PFIZER,,26,YR,,F,Y,33,KG,20180305,,OT,LS,LS,EFAVIRENZ.,Anaemia;Condition aggravated;Cough;Failure to thrive;Hepatic enzyme increased;Pyrexia;Vomiting;Weight decreased,145547722,HO,,,145547722,1,20170719,,,,145547722,1,Tuberculosis
14555618,145556181,1,I,,20180212,20180221,20180221,EXP,,IN-HETERO CORPORATE-HET2018IN00127,HETERO,,31,YR,,M,Y,,,20180220,,OT,IN,IN,STAVUDINE+LAMIVUDINE+EFAVIRENZ,Immune reconstitution inflammatory syndrome;Meningitis cryptococcal,145556181,DE,,,,,,,,,145556181,1,HIV infection
14560895,145608951,1,I,,20180212,20180222,20180222,EXP,,PT-WEST-WARD PHARMACEUTICALS CORP.-PT-H14001-18-01265,WESTWARD,"CARDOSO C,TRIGO D,PACHECO P. PULMONAR HYPERTENSION IN HIV/AIDS INFECTION: A RARE DISEASE. VER CLIN HOSP PROF DR FERNANDO FONSECA 2016;4(1/2):41-44.",62,YR,,F,Y,,,20180222,,MD,PT,PT,TENOFOVIR/EMTRICITABINE/EFAVIRENZ,Dyspnoea;Fatigue;Hypoxia,145608951,HO,,,,,,,,,145608951,1,Product used for unknown indication
14562137,145621371,1,I,20171115,,20180222,20180222,DIR,,,FDA-CTU,,51,YR,,F,N,97.52,KG,,Y,CN,US,US,SUSTIVA,Asthenia;Blood glucose increased;Cough;Disorientation;Feeling abnormal;Gingival bleeding;Gingival recession;Heart rate increased;Pruritus;Thirst;Vision blurred,145621371,DS,145621371,CSM,145621371,1,20170710,20171115,,,145621371,1,HIV infection
14564233,145642331,1,I,,20180219,20180222,20180222,EXP,,IE-VIIV HEALTHCARE LIMITED-IE2018028715,VIIV,"BUTLER K, INSHAW J, FORD D, BERNAYS S, SCOTT K, KENNY J.ET.AL BREATHER (PENTA 16) SHORT-CYCLE THERAPY (SCT)(5 DAYS ON/2 DAYS OFF) IN YOUNG PEOPLE WITH CHRONIC HUMAN IMMUNODEFICIENCY VIRUS INFECTION: AN OPEN, RANDOMISED, PARALLEL-GROUP PHASE II/III TRIAL. HEALTH TECHNOLOGY ASSESSMENT. 2016 JUN;20(49):1-107. DOI: 10.3310/HTA20490",,,C,,Y,,,20180222,,MD,IE,IE,EFAVIRENZ.,Virologic failure,145642331,OT,,,,,,,,,145642331,1,HIV infection
14564238,145642381,1,I,,20180219,20180222,20180222,EXP,,IE-GLAXOSMITHKLINE-IE2018028715,GLAXOSMITHKLINE,"BUTLER K, INSHAW J, FORD D, BERNAYS S, SCOTT K, KENNY J.ET.AL BREATHER (PENTA 16) SHORT-CYCLE THERAPY (SCT)(5 DAYS ON/2 DAYS OFF) IN YOUNG PEOPLE WITH CHRONIC HUMAN IMMUNODEFICIENCY VIRUS INFECTION: AN OPEN, RANDOMISED, PARALLEL-GROUP PHASE II/III TRIAL. HEALTH TECHNOLOGY ASSESSMENT. 2016 JUN;20(49):1-107. DOI: 10.3310/HTA20490",,,C,,Y,,,20180222,,MD,IE,IE,EFAVIRENZ.,Virologic failure,145642381,OT,,,,,,,,,145642381,1,HIV infection
14564417,145644171,1,I,,20180219,20180222,20180222,EXP,,GB-GILEAD-2018-0322420,GILEAD,,54,YR,A,M,Y,,,20180222,,CN,GB,GB,EFAVIRENZ.,Anal fistula infection,145644171,HO,,,,,,,,,145644171,1,HIV infection
14565194,145651941,1,I,20171107,20180208,20180223,20180223,EXP,,GB-AUROBINDO-AUR-APL-2018-009154,AUROBINDO,,47,YR,,F,Y,,,20180222,,MD,GB,GB,EFAVIRENZ.,Acute hepatic failure;Product substitution issue,145651941,HO,,,145651941,1,20170501,20170516,,,145651941,1,HIV infection
14565353,145653531,1,I,,20180208,20180223,20180223,EXP,,GB-AUROBINDO-AUR-APL-2018-009313,AUROBINDO,,56,YR,,M,Y,,,20180223,,OT,GB,GB,EFAVIRENZ.,Pathogen resistance;Viral mutation identified,145653531,OT,,,,,,,,,145653531,1,HIV infection
14568246,145682461,1,I,20180209,20180210,20180223,20180223,EXP,,BR-CIPLA LTD.-2018BR06248,CIPLA,,,,,,Y,,,20180223,,OT,BR,BR,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Abortion spontaneous;Exposure during pregnancy,145682461,OT,,,145682461,1,20180103,,,,145682461,1,HIV infection
14571020,145710201,1,I,20060406,20061011,20180226,20180226,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMSP2006-00643,BRISTOL MYERS SQUIBB,,37,YR,,M,Y,,,20180226,,MD,JP,JP,SUSTIVA,Dysgeusia;General physical health deterioration;Infection;Liver function test abnormal;Neutropenia,145710201,OT,,,145710201,1,20060323,20061022,,,145710201,1,Oral candidiasis
14571070,145710701,1,I,20000405,20020729,20180226,20180226,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-11970746,BRISTOL MYERS SQUIBB,,35,YR,,M,Y,,,20180226,,OT,US,JP,EFAVIRENZ.,Gastrointestinal haemorrhage;Haematochezia;Hepatic function abnormal;Hyperlipidaemia;Shock haemorrhagic,145710701,DE,,,145710701,1,19970930,20010928,,,145710701,1,Acquired immunodeficiency syndrome
14573452,145734522,2,F,20180216,20180323,20180226,20180327,EXP,,US-JAZZ-2018-US-003422,JAZZ,,58,YR,,M,Y,,,20180327,,,US,US,EFAVIRENZ.,Death,145734522,DE,,,145734522,1,201507,201507,,,145734522,1,Narcolepsy
14576417,145764171,1,I,20001114,20010403,20180227,20180227,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-10784924,BRISTOL MYERS SQUIBB,,65,YR,,M,Y,48,KG,20180227,,OT,JP,JP,EFAVIRENZ.,AIDS related complex,145764171,OT,,,145764171,1,20000615,20000914,,,145764171,1,Acquired immunodeficiency syndrome
14586226,145862261,1,I,,20180214,20180301,20180301,EXP,,UG-MYLANLABS-2018M1012525,MYLAN,,26,YR,,F,Y,,,20180301,,OT,UG,UG,TENOFOVIR DF/LAMIVUDINE/EFAVIRENZ TABLETS 300/300/600MG,Malaria;Maternal exposure during pregnancy;Stillbirth,145862261,OT,,,145862261,1,20170118,,,,145862261,1,HIV infection
14587331,145873311,1,I,20171018,20180221,20180301,20180301,EXP,,LS-PFIZER INC-2018080539,PFIZER,,26,YR,,F,Y,33,KG,20180301,,OT,LS,LS,EFAVIRENZ.,Anaemia;Condition aggravated;Cough;Failure to thrive;Hepatic enzyme abnormal;Pyrexia;Vomiting;Weight decreased,145873311,HO,,,145873311,1,20171114,,,,145873311,1,Tuberculosis
14589604,145896041,1,I,,20180217,20180302,20180302,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-015867,BRISTOL MYERS SQUIBB,,54,YR,,M,Y,67,KG,20180302,,MD,GB,GB,SUSTIVA,Nightmare;Sleep disorder;Suicidal ideation,145896041,OT,,,,,,,,,145896041,1,HIV test positive
14592833,145928332,2,F,201707,20180306,20180302,20180313,EXP,,TR-GILEAD-2018-0322917,GILEAD,,45,YR,A,M,Y,,,20180313,,MD,TR,TR,EFAVIRENZ.,Herpes zoster;Treatment noncompliance,145928332,HO,,,145928332,1,2013,,,,145928332,1,HIV infection
14593834,145938341,1,I,,20180220,20180302,20180302,EXP,,TR-GILEAD-2018-0322713,GILEAD,,44,YR,A,M,Y,,,20180302,,MD,TR,TR,EFAVIRENZ.,Drug resistance;Gene mutation identification test positive;Treatment noncompliance;Virologic failure,145938341,OT,,,,,,,,,145938341,1,HIV infection
14595397,145953971,1,I,,20170802,20180302,20180302,EXP,,US-GILEAD-2017-0287264,GILEAD,,49,YR,A,F,Y,,,20180302,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Back pain;Loss of consciousness;Pneumonia,145953971,OT,,,145953971,1,2017,,,,145953971,1,HIV infection
14595944,145959441,1,I,,20180216,20180303,20180303,EXP,,GB-AUROBINDO-AUR-APL-2018-010500,AUROBINDO,,54,YR,,M,Y,67,KG,20180303,,MD,GB,GB,EFAVIRENZ.,Nightmare;Sleep disorder;Suicidal ideation,145959441,DS,,,,,,,,,145959441,1,HIV test positive
14596055,145960551,1,I,20001221,20180226,20180303,20180303,EXP,,FR-VIIV HEALTHCARE LIMITED-FR2018031833,VIIV,,37,YR,,F,Y,,,20180303,,CN,US,FR,EFAVIRENZ.,Exposure during pregnancy;Gestational diabetes;Normal newborn,145960551,OT,,,145960551,2,19960814,,,,145960551,1,Antiretroviral therapy
14596130,145961301,1,I,20001221,20180226,20180303,20180303,EXP,,FR-GLAXOSMITHKLINE-FR2018031833,GLAXOSMITHKLINE,,37,YR,,F,Y,,,20180303,,CN,US,FR,EFAVIRENZ.,Exposure during pregnancy;Gestational diabetes;Normal newborn,145961301,OT,,,145961301,2,19960814,,,,145961301,1,Antiretroviral therapy
14598424,145984241,1,I,,20180219,20180305,20180305,EXP,,US-MYLANLABS-2018M1013573,MYLAN,"MORGAN MK, HARTZELL JD, BLAYLOCK JM. SEPSIS MIMICKER IN AN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PATIENT. MIL-MED 2017;182:E1861-E1863.",22,YR,,M,Y,,,20180305,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Acute kidney injury;Hypersensitivity;Hypotension,145984241,HO,,,,,,,,,145984241,1,HIV infection
14598555,145985551,1,I,,20180209,20180305,20180305,EXP,,BR-MYLANLABS-2018M1011927,MYLAN,,,,,M,Y,2.37,KG,20180305,,OT,BR,BR,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Congenital skin dimples;Foetal exposure during pregnancy,145985551,CA,,,145985551,1,20170821,,,,145985551,1,HIV infection
14599811,145998111,1,I,,20180226,20180305,20180305,EXP,,PT-VIIV HEALTHCARE LIMITED-PT2018031666,VIIV,ESTEVES T.. MATERNAL DRUG USE DURING PREGNANCY AND INFANCY -THE IMPORTANCE OF A MULTIDISCIPLINARY APPROACH.. REVISTA PORTUGUESA DE CLINICA GERAL.. 2011;27::458-64,27,YR,,F,Y,,,20180305,,OT,PT,PT,EFAVIRENZ.,Caesarean section;Drug abuse;Live birth;Maternal exposure during pregnancy;Pregnancy on oral contraceptive;Product use issue,145998111,OT,,,,,,,,,145998111,1,HIV infection
14599813,145998131,1,I,,20180226,20180305,20180305,EXP,,PT-GLAXOSMITHKLINE-PT2018031666,GLAXOSMITHKLINE,ESTEVES T.. MATERNAL DRUG USE DURING PREGNANCY AND INFANCY -THE IMPORTANCE OF A MULTIDISCIPLINARY APPROACH.. REVISTA PORTUGUESA DE CLINICA GERAL.. 2011;27::458-64,27,YR,,F,Y,,,20180305,,OT,PT,PT,EFAVIRENZ.,Caesarean section;Drug abuse;Live birth;Maternal exposure during pregnancy;Pregnancy on oral contraceptive;Product use issue,145998131,OT,,,,,,,,,145998131,1,HIV infection
14603819,146038191,1,I,20180220,20180227,20180306,20180306,EXP,,LS-JNJFOC-20180238311,JANSSEN,,29,YR,A,F,Y,39,KG,20180306,,MD,LS,LS,EFAVIRENZ.,Arthralgia;Asthenia;Odynophagia;Platelet count decreased;Respiratory failure;Vomiting;White blood cell count increased,146038191,DE,,,146038191,1,20180126,,,,146038191,1,Tuberculosis
14604248,146042481,1,I,,20180226,20180306,20180306,EXP,,ZA-GILEAD-2018-0323708,GILEAD,"CHETTY T, THORNE C, COUTSOUDIS A. PRETERM DELIVERY AND SMALL-FOR-GESTATION OUTCOMES IN HIV-INFECTED PREGNANT WOMEN ON ANTIRETROVIRAL THERAPY IN RURAL SOUTH AFRICA: RESULTS FROM A COHORT STUDY, 2010-2015. PLOS ONE. 2018;13(2):N/A",,,A,F,Y,,,20180306,,OT,ZA,ZA,EFAVIRENZ.,Maternal exposure during pregnancy;Premature delivery,146042481,OT,,,,,,,,,146042481,1,HIV infection
14604272,146042721,1,I,,20180226,20180306,20180306,EXP,,ZA-GILEAD-2018-0324575,GILEAD,"CHETTY T, THORNE C, COUTSOUDIS A. PRETERM DELIVERY AND SMALL-FOR-GESTATION OUTCOMES IN HIV-INFECTED PREGNANT WOMEN ON ANTIRETROVIRAL THERAPY IN RURAL SOUTH AFRICA: RESULTS FROM A COHORT STUDY, 2010-2015. PLOS ONE. 2018;13(2):N/A",,,A,F,Y,,,20180306,,OT,ZA,ZA,EFAVIRENZ.,Maternal exposure during pregnancy;Premature delivery,146042721,OT,,,,,,,,,146042721,1,HIV infection
14604417,146044171,1,I,,20180226,20180306,20180306,EXP,,ZA-GILEAD-2018-0324581,GILEAD,"CHETTY T, THORNE C, COUTSOUDIS A. PRETERM DELIVERY AND SMALL-FOR-GESTATION OUTCOMES IN HIV-INFECTED PREGNANT WOMEN ON ANTIRETROVIRAL THERAPY IN RURAL SOUTH AFRICA: RESULTS FROM A COHORT STUDY, 2010-2015. PLOS ONE. 2018;13(2):N/A",,,A,F,Y,,,20180306,,OT,ZA,ZA,EFAVIRENZ.,Maternal exposure during pregnancy;Premature delivery,146044171,OT,,,,,,,,,146044171,1,HIV infection
14604418,146044181,1,I,,20180226,20180306,20180306,EXP,,ZA-GILEAD-2018-0324579,GILEAD,"CHETTY T, THORNE C, COUTSOUDIS A. PRETERM DELIVERY AND SMALL-FOR-GESTATION OUTCOMES IN HIV-INFECTED PREGNANT WOMEN ON ANTIRETROVIRAL THERAPY IN RURAL SOUTH AFRICA: RESULTS FROM A COHORT STUDY, 2010-2015. PLOS ONE. 2018;13(2):N/A",,,A,F,Y,,,20180306,,OT,ZA,ZA,EFAVIRENZ.,Maternal exposure during pregnancy;Premature delivery,146044181,OT,,,,,,,,,146044181,1,HIV infection
14604419,146044191,1,I,,20180226,20180306,20180306,EXP,,ZA-GILEAD-2018-0324577,GILEAD,"CHETTY T, THORNE C, COUTSOUDIS A. PRETERM DELIVERY AND SMALL-FOR-GESTATION OUTCOMES IN HIV-INFECTED PREGNANT WOMEN ON ANTIRETROVIRAL THERAPY IN RURAL SOUTH AFRICA: RESULTS FROM A COHORT STUDY, 2010-2015. PLOS ONE. 2018;13(2):N/A",,,A,F,Y,,,20180306,,OT,ZA,ZA,EFAVIRENZ.,Maternal exposure during pregnancy;Premature delivery,146044191,OT,,,,,,,,,146044191,1,HIV infection
14604420,146044201,1,I,,20180226,20180306,20180306,EXP,,ZA-GILEAD-2018-0324578,GILEAD,"CHETTY T, THORNE C, COUTSOUDIS A. PRETERM DELIVERY AND SMALL-FOR-GESTATION OUTCOMES IN HIV-INFECTED PREGNANT WOMEN ON ANTIRETROVIRAL THERAPY IN RURAL SOUTH AFRICA: RESULTS FROM A COHORT STUDY, 2010-2015. PLOS ONE. 2018;13(2):N/A",,,A,F,Y,,,20180306,,OT,ZA,ZA,EFAVIRENZ.,Maternal exposure during pregnancy;Premature delivery,146044201,OT,,,,,,,,,146044201,1,HIV infection
14604432,146044321,1,I,,20180226,20180306,20180306,EXP,,ZA-GILEAD-2018-0324576,GILEAD,"CHETTY T, THORNE C, COUTSOUDIS A. PRETERM DELIVERY AND SMALL-FOR-GESTATION OUTCOMES IN HIV-INFECTED PREGNANT WOMEN ON ANTIRETROVIRAL THERAPY IN RURAL SOUTH AFRICA: RESULTS FROM A COHORT STUDY, 2010-2015. PLOS ONE. 2018;13(2):N/A",,,A,F,Y,,,20180306,,OT,ZA,ZA,EFAVIRENZ.,Maternal exposure during pregnancy;Premature delivery,146044321,OT,,,,,,,,,146044321,1,HIV infection
14604433,146044331,1,I,,20180226,20180306,20180306,EXP,,ZA-GILEAD-2018-0324582,GILEAD,"CHETTY T, THORNE C, COUTSOUDIS A. PRETERM DELIVERY AND SMALL-FOR-GESTATION OUTCOMES IN HIV-INFECTED PREGNANT WOMEN ON ANTIRETROVIRAL THERAPY IN RURAL SOUTH AFRICA: RESULTS FROM A COHORT STUDY, 2010-2015. PLOS ONE. 2018;13(2):N/A",,,A,F,Y,,,20180306,,OT,ZA,ZA,EFAVIRENZ.,Maternal exposure during pregnancy;Premature delivery,146044331,OT,,,,,,,,,146044331,1,HIV infection
14604434,146044341,1,I,,20180226,20180306,20180306,EXP,,ZA-GILEAD-2018-0324580,GILEAD,"CHETTY T, THORNE C, COUTSOUDIS A. PRETERM DELIVERY AND SMALL-FOR-GESTATION OUTCOMES IN HIV-INFECTED PREGNANT WOMEN ON ANTIRETROVIRAL THERAPY IN RURAL SOUTH AFRICA: RESULTS FROM A COHORT STUDY, 2010-2015. PLOS ONE. 2018;13(2):N/A",,,A,F,Y,,,20180306,,OT,ZA,ZA,EFAVIRENZ.,Maternal exposure during pregnancy;Premature delivery,146044341,OT,,,,,,,,,146044341,1,HIV infection
14604439,146044391,1,I,,20180226,20180306,20180306,EXP,,ZA-GILEAD-2018-0324583,GILEAD,"CHETTY T, THORNE C, COUTSOUDIS A. PRETERM DELIVERY AND SMALL-FOR-GESTATION OUTCOMES IN HIV-INFECTED PREGNANT WOMEN ON ANTIRETROVIRAL THERAPY IN RURAL SOUTH AFRICA: RESULTS FROM A COHORT STUDY, 2010-2015. PLOS ONE. 2018;13(2):N/A",,,A,F,Y,,,20180306,,OT,ZA,ZA,EFAVIRENZ.,Maternal exposure during pregnancy;Premature delivery,146044391,OT,,,,,,,,,146044391,1,HIV infection
14604440,146044401,1,I,,20180226,20180306,20180306,EXP,,ZA-GILEAD-2018-0324584,GILEAD,"CHETTY T, THORNE C, COUTSOUDIS A. PRETERM DELIVERY AND SMALL-FOR-GESTATION OUTCOMES IN HIV-INFECTED PREGNANT WOMEN ON ANTIRETROVIRAL THERAPY IN RURAL SOUTH AFRICA: RESULTS FROM A COHORT STUDY, 2010-2015. PLOS ONE. 2018;13(2):N/A",,,A,F,Y,,,20180306,,OT,ZA,ZA,EFAVIRENZ.,Maternal exposure during pregnancy;Premature delivery,146044401,OT,,,,,,,,,146044401,1,HIV infection
14604441,146044411,1,I,,20180226,20180306,20180306,EXP,,ZA-GILEAD-2018-0324585,GILEAD,"CHETTY T, THORNE C, COUTSOUDIS A. PRETERM DELIVERY AND SMALL-FOR-GESTATION OUTCOMES IN HIV-INFECTED PREGNANT WOMEN ON ANTIRETROVIRAL THERAPY IN RURAL SOUTH AFRICA: RESULTS FROM A COHORT STUDY, 2010-2015. PLOS ONE. 2018;13(2):N/A",,,A,F,Y,,,20180306,,OT,ZA,ZA,EFAVIRENZ.,Maternal exposure during pregnancy;Premature delivery,146044411,OT,,,,,,,,,146044411,1,HIV infection
14604442,146044421,1,I,,20180226,20180306,20180306,EXP,,ZA-GILEAD-2018-0324586,GILEAD,"CHETTY T, THORNE C, COUTSOUDIS A. PRETERM DELIVERY AND SMALL-FOR-GESTATION OUTCOMES IN HIV-INFECTED PREGNANT WOMEN ON ANTIRETROVIRAL THERAPY IN RURAL SOUTH AFRICA: RESULTS FROM A COHORT STUDY, 2010-2015. PLOS ONE. 2018;13(2):N/A",,,A,F,Y,,,20180306,,OT,ZA,ZA,EFAVIRENZ.,Maternal exposure during pregnancy;Premature delivery,146044421,OT,,,,,,,,,146044421,1,HIV infection
14605422,146054221,1,I,,20180301,20180306,20180306,EXP,,GB-GILEAD-2018-0324072,GILEAD,,,,,M,Y,,,20180306,,PH,GB,GB,EFAVIRENZ.,Death,146054221,OT,,,,,,,,,146054221,1,HIV infection
14607636,146076361,1,I,,20180222,20180307,20180307,EXP,,AU-MYLANLABS-2018M1014320,MYLAN,"MEDLAND NA, CHOW EPF, WALKER RG, CHEN M, READ TRH, FAIRLEY CK. INCIDENCE OF RENAL FANCONI SYNDROME IN PATIENTS TAKING ANTIRETROVIRAL THERAPY INCLUDING TENOFOVIR DISOPROXIL FUMARATE. INT-J-STD-AIDS 2018;29(3):227-236.",,,A,M,Y,,,20180307,,OT,AU,AU,EFAVIRENZ.,Anaemia;Fanconi syndrome acquired,146076361,OT,,,,,,,,,146076361,1,HIV infection
14607848,146078481,1,I,,20180222,20180307,20180307,EXP,,AU-MYLANLABS-2018M1014345,MYLAN,"MEDLAND NA, CHOW EPF, WALKER RG, CHEN M, READ TRH, FAIRLEY CK. INCIDENCE OF RENAL FANCONI SYNDROME IN PATIENTS TAKING ANTIRETROVIRAL THERAPY INCLUDING TENOFOVIR DISOPROXIL FUMARATE. INT-J-STD-AIDS 2018;29(3):227-236.",,,A,M,Y,,,20180307,,OT,AU,AU,EFAVIRENZ.,Drug interaction;Fanconi syndrome acquired,146078481,OT,,,,,,,,,146078481,1,HIV infection
14608010,146080101,1,I,,20180305,20180307,20180307,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK038183,GLAXOSMITHKLINE,,52,YR,,M,Y,,,20180307,,OT,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,146080101,OT,,,,,,,,,146080101,1,HIV infection
14610366,146103661,1,I,,20180226,20180307,20180307,EXP,CA-HEALTH CANADA-E2B_01366855,CA-ALLERGAN-1812285US,ALLERGAN,,44,YR,,M,Y,,,20180307,,OT,CA,CA,SUSTIVA,Anxiety;Contraindicated product administered;Depression;Depression suicidal;Depressive symptom;Drug interaction;Off label use;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,146103661,OT,,,,,,,,,146103661,1,Psychotic disorder
14612446,146124461,1,I,,20180305,20180308,20180308,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2018GSK038183,VIIV,,52,YR,,M,Y,,,20180308,,OT,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,146124461,OT,,,,,,,,,146124461,1,HIV infection
14620011,146200111,1,I,20170823,20180224,20180309,20180309,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-018331,BRISTOL MYERS SQUIBB,,34,YR,,M,Y,84,KG,20180309,,PH,GB,GB,SUSTIVA,Nightmare,146200111,OT,,,146200111,1,20170823,20171123,,,146200111,1,Acute HIV infection
14621083,146210831,1,I,20170823,20180223,20180310,20180310,EXP,GB-MHRA-EYC 00171579,GB-AUROBINDO-AUR-APL-2018-012110,AUROBINDO,,34,YR,,M,Y,84,KG,20180310,,PH,GB,GB,EFAVIRENZ.,Nightmare,146210831,OT,,,146210831,1,20170823,20171123,,,146210831,1,Acute HIV infection
14623366,146233662,2,F,,20180312,20180312,20180316,EXP,,AU-STRIDES ARCOLAB LIMITED-2018SP001663,STRIDES,"MEDLAND NA, CHOW EPF, WALKER RG, CHEN M, READ TRH, FAIRLEY CK. INCIDENCE OF RENAL FANCONI SYNDROME IN PATIENTS TAKING ANTIRETROVIRAL THERAPY INCLUDING TENOFOVIR DISOPROXIL FUMARATE. INT-J-STDAIDS. 2017;29(3):227-236",,,,,Y,,,20180316,,OT,AU,AU,EFAVIRENZ.,Acute kidney injury;Anaemia;Fanconi syndrome;Glycosuria;Proteinuria,146233662,OT,,,,,,,,,146233662,1,HIV infection
14625189,146251891,1,I,,20180226,20180312,20180312,EXP,,IE-GLENMARK PHARMACEUTICALS-2018GMK032961,GLENMARK,,37,YR,,F,Y,,,20180312,,CN,IE,IE,EFAVIRENZ.,Cushingoid;Leukopenia;Off label use;Skin atrophy,146251891,OT,,,,,,,,,146251891,1,Product used for unknown indication
14626923,146269231,1,I,,20180226,20180312,20180312,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-018763,BRISTOL MYERS SQUIBB,,44,YR,,F,Y,,,20180312,,OT,FR,FR,EFAVIRENZ.,Drug reaction with eosinophilia and systemic symptoms,146269231,HO,,,146269231,1,199902,,,,146269231,1,HIV infection
14631761,146317613,3,F,,20180320,20180313,20180327,EXP,,ES-GILEAD-2018-0325136,GILEAD,,46,YR,A,,Y,,,20180327,,MD,ES,ES,EFAVIRENZ.,Drug withdrawal maintenance therapy;Nervous system disorder;Neurodermatitis;Treatment noncompliance;Weight decreased,146317613,OT,,,146317613,1,200805,,,,146317613,1,HIV infection
14631821,146318211,1,I,,20180228,20180313,20180313,EXP,,"US-LANNETT COMPANY, INC.-US-2018LAN000518",LANNETT,"OGBUAGU O, HAO R, VIRATA M, VILLANUEVA MS, MALINIS M. EFFICACY OF AN 8-WEEK COURSE OF SOFOSBUVIR AND LEDIPASVIR FOR THE TREATMENT OF HCV INFECTION IN SELECTED HIV-INFECTED PATIENTS. F1000RES. 2017;6620",,,A,M,Y,,,20180313,,OT,US,US,EFAVIRENZ.,Acute kidney injury,146318211,OT,,,,,,,,,146318211,1,Antiretroviral therapy
14633105,146331051,1,I,,20180227,20180313,20180313,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-018769,BRISTOL MYERS SQUIBB,,6,YR,,F,Y,,,20180313,,MD,US,US,EFAVIRENZ.,Hypersensitivity,146331051,OT,,,,,,,,,146331051,1,HIV infection
14633200,146332002,2,F,,20180316,20180313,20180323,EXP,,PT-ABBVIE-18P-130-2283024-00,ABBVIE,"NUNES C, ROCHA S, ESTEVES T. DRUG ADDICTION DURING PREGNANCY AND MOTHERHOOD  THE IMPORTANCE OF A MULTIDISCIPLINARY APPROACH. REVISTA PORTUGUESA DE CLINICA GERAL. 2011;27:458-564.",27,YR,,F,Y,,,20180323,,OT,COUNTRY NOT SPECIFIED,PT,EFAVIRENZ.,Exposure during pregnancy,,,,,146332002,4,2007,,,,146332002,1,HIV infection
14638395,146383951,1,I,,20161013,20180314,20180314,PER,,US-PFIZER INC-2016481048,PFIZER,,87,YR,,M,Y,,,20180314,,MD,US,US,SUSTIVA,Neoplasm progression,,,,,,,,,,,146383951,1,Metastatic renal cell carcinoma
14641442,146414421,1,I,20170101,20180228,20180315,20180315,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-020295,BRISTOL MYERS SQUIBB,,44,YR,,M,Y,,,20180315,,MD,FR,FR,SUSTIVA,Renal colic,146414421,OT,,,,,,,,,146414421,1,Antiretroviral therapy
14645809,146458091,1,I,,20180301,20180316,20180316,EXP,,FR-CIPLA LTD.-2018FR11841,CIPLA,"PRESSIAT C, AMORISSANI-FOLQUET M, YONABA C, TRELUYER JM, DAHOUROU DL, EBOUA F ET.AL.,. PHARMACOKINETICS OF EFAVIRENZ IN 2-3 YEARS OLD CHILDREN: A HIGH DOSE OF 25 MG/KG PER DAY. ANTIMICROBIAL AGENTS AND CHEMOTHEMOTHERAPY. 2017;1 TO 25",,,,,Y,,,20180316,,OT,FR,FR,EFAVIRENZ.,Sleep disorder,146458091,OT,,,,,,,,,146458091,1,HIV infection
14648787,146487871,1,I,20171227,20180312,20180316,20180316,EXP,,PHHY2018ZA043408,SANDOZ,,22,YR,,M,Y,41.8,KG,20180316,,CN,ZA,ZA,EFAVIRENZ.,Bundle branch block left;Chest pain;Electrocardiogram QT prolonged;Incorrect drug administration duration,146487871,LT,,,146487871,1,20170330,20171227,,,146487871,1,Pulmonary tuberculosis
14653492,146534921,1,I,,20180305,20180319,20180319,EXP,,IE-VELOXIS PHARMACEUTICALS-2044048,VELOXIS PHARMACEUTICALS,,37,YR,,F,Y,,,20180319,,OT,IE,IE,EFAVIRENZ.,Cushingoid;Drug ineffective;Intentional product use issue;Leukopenia;Skin atrophy,146534921,OT,,,,,,,,,146534921,1,Sarcoidosis
14662859,146628591,1,I,,20180306,20180321,20180321,EXP,,TH-NOVITIUM PHARMA LLC-2018-TH-000005,NOVITIUM PHARMA,"TEMPARK T, SATAPORNPONG P, RERKNIMITR P, NAKKAM N, SAKSIT N, WATTANAKRAI P, ET AL..DAPSONE-INDUCED SEVERE CUTANEOUS ADVERSE DRUG REACTIONS ARE STRONGLY LINKED WITH HLA-B*13:01 ALLELE IN THE THAI POPULATION.PHARMACOGENETICS AND GENOMICS.2017;27(12):429-437.",57,YR,A,F,Y,,,20180321,,OT,TH,TH,EFAVIRENZ.,Drug reaction with eosinophilia and systemic symptoms;Hepatitis;Leukocytosis;Product use in unapproved indication;Purpura;Pyrexia;Rash maculo-papular;Skin exfoliation,146628591,LT,,,,,,,,,146628591,1,Prophylaxis against HIV infection
14662894,146628941,1,I,,20180306,20180321,20180321,EXP,,TH-NOVITIUM PHARMA LLC-2018-TH-000010,NOVITIUM PHARMA,"TEMPARK T, SATAPORNPONG P, RERKNIMITR P, NAKKAM N, SAKSIT N, WATTANAKRAI P, ET AL..DAPSONE-INDUCED SEVERE CUTANEOUS ADVERSE DRUG REACTIONS ARE STRONGLY LINKED WITH HLA-B*13:01 ALLELE IN THE THAI POPULATION?.PHARMACOGENETICS AND GENOMICS.2017;27(12):429-437.",56,YR,A,M,Y,,,20180321,,OT,TH,TH,Efavirenz/tenofovir/emtricitabine,Drug reaction with eosinophilia and systemic symptoms;Hepatitis;Mouth ulceration;Papule;Product use in unapproved indication;Pyrexia,146628941,LT,,,,,,,,,146628941,1,Pneumocystis jirovecii pneumonia
14662921,146629211,1,I,,20180306,20180321,20180321,EXP,,TH-NOVITIUM PHARMA LLC-2018-TH-000014,NOVITIUM PHARMA,"TEMPARK T, SATAPORNPONG P, RERKNIMITR P, NAKKAM N, SAKSIT N, WATTANAKRAI P, ET AL.DAPSONE-INDUCED SEVERE CUTANEOUS ADVERSE DRUG REACTIONS ARE STRONGLY LINKED WITH HLA-B*13:01 ALLELE IN THE THAI POPULATION.PHARMACOGENETICS AND GENOMICS.2017;27(12):429-437.",41,YR,A,M,Y,,,20180321,,OT,TH,TH,EFAVIRENZ.,Hepatitis;Product use in unapproved indication;Purpura;Pyrexia;Rash maculo-papular;Skin exfoliation;Stevens-Johnson syndrome,146629211,LT,,,,,,,,,146629211,1,Prophylaxis against HIV infection
14663072,146630721,1,I,,20180308,20180321,20180321,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-023073,BRISTOL MYERS SQUIBB,,66,YR,,M,Y,,,20180321,,PH,GB,GB,EFAVIRENZ.,Death,146630721,OT,,,,,,,,,146630721,1,HIV infection
14664785,146647851,1,I,20180131,20180316,20180321,20180321,EXP,,AM-PFIZER INC-2018115023,PFIZER,,56,YR,,M,Y,,,20180321,,OT,AM,AM,EFAVIRENZ.,Acute kidney injury;Anxiety;Blood creatinine increased;Hypersensitivity,146647851,OT,,,146647851,1,20170223,20170515,,,146647851,1,Pulmonary tuberculosis
14668853,146688531,1,I,,20180308,20180322,20180322,EXP,,GB-AUROBINDO-AUR-APL-2018-016210,AUROBINDO,,66,YR,,M,Y,,,20180322,,PH,GB,GB,EFAVIRENZ.,Death,146688531,DE,,,,,,,,,146688531,1,HIV infection
14669548,146695481,1,I,,20180315,20180322,20180322,EXP,,FR-VIIV HEALTHCARE LIMITED-FR2018044235,VIIV,COLIN D. HYPERSENSITIVITY SYNDROME ASSOCIATED WITH EFAVIRENZ THERAPY.. CLINICAL INFECTIOUS DISEASES. 2000;30:227-8,44,YR,,F,Y,,,20180322,,OT,FR,FR,EFAVIRENZ.,Drug reaction with eosinophilia and systemic symptoms,146695481,OT,,,146695481,1,199902,,,,146695481,1,HIV infection
14670449,146704491,1,I,,20180315,20180322,20180322,EXP,,FR-GLAXOSMITHKLINE-FR2018044235,GLAXOSMITHKLINE,COLIN D. HYPERSENSITIVITY SYNDROME ASSOCIATED WITH EFAVIRENZ THERAPY.. CLINICAL INFECTIOUS DISEASES. 2000;30:227-8,44,YR,,F,Y,,,20180322,,OT,FR,FR,EFAVIRENZ.,Drug reaction with eosinophilia and systemic symptoms,146704491,HO,,,146704491,1,199902,,,,146704491,1,HIV infection
14673095,146730951,1,I,,20180314,20180323,20180323,EXP,,ZA-HETERO CORPORATE-HET2018ZA00216,HETERO,,35,YR,,F,Y,,,20180323,,OT,ZA,ZA,EFAVIRENZ.,Exposure during pregnancy;Foetal death;Haemoglobin decreased;Platelet count decreased;Vitamin B12 deficiency,146730951,OT,,,146730951,1,20180214,,,,146730951,1,HIV infection
14676686,146766861,1,I,,20180313,20180324,20180324,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-025144,BRISTOL MYERS SQUIBB,,35,YR,,F,Y,,,20180324,,OT,ZA,ZA,EFAVIRENZ.,Haemoglobin decreased;Maternal exposure during pregnancy;Platelet count decreased;Ventricular extrasystoles;Vitamin B12 deficiency,146766861,HO,,,146766861,1,20180214,,,,146766861,1,HIV infection
14679807,146798071,1,I,,20180319,20180326,20180326,EXP,,BR-ABBVIE-18P-020-2295403-00,ABBVIE,"DA FONSECA M, MESQUITA L, DA SILVA R, MORIZOT E. PANRETINAL RITONAVIR-INDUCED RETINOPATHY: A REPORT OF LONG-TERM USEPANRETINAL RITONAVIR-INDUCED RETINOPATHY: A REPORT OF LONG-TERM USE. RETINAL CASES + BRIEF REPORTS. 2018 MAR 15;1-3.",52,YR,,M,Y,,,20180326,,MD,COUNTRY NOT SPECIFIED,BR,EFAVIRENZ.,Retinal toxicity;Retinopathy,146798071,OT,,,,,,,,,146798071,1,HIV infection
14680403,146804031,1,I,,20180312,20180326,20180326,EXP,,FR-TEVA-2018-FR-872166,TEVA,"CEZ A, BROCHERIOU I, LESCURE F-X, ADAM C, GIRARD P-M, PIALOUX G, ET AL. DECREASED EXPRESSION OF MEGALIN AND CUBILIN AND ALTERED MITOCHONDRIAL ACTIVITY IN TENOFOVIR NEPHROTOXICITY. HUM-PATHOL 2018;73:89-101.",54,YR,,M,Y,,,20180326,,MD,FR,FR,EFAVIRENZ.,Fanconi syndrome acquired;Renal tubular dysfunction,146804031,OT,,,,,,,,,146804031,1,Antiretroviral therapy
14682508,146825081,1,I,,20180313,20180327,20180327,EXP,,FR-AUROBINDO-AUR-APL-2018-016242,AUROBINDO,,44,YR,,F,Y,,,20180327,,OT,FR,FR,EFAVIRENZ.,Drug reaction with eosinophilia and systemic symptoms,,,,,146825081,1,199902,,,,146825081,1,HIV infection
14685358,146853581,1,I,,20180314,20180327,20180327,EXP,,"AU-LANNETT COMPANY, INC.-AU-2018LAN000566",LANNETT,"MEDLAND NA, CHOW EPF, WALKER RG, CHEN M, READ TRH, FAIRLEY CK. INCIDENCE OF RENAL FANCONI SYNDROME IN PATIENTS TAKING ANTIRETROVIRAL THERAPY INCLUDING TENOFOVIR DISOPROXIL FUMARATE. INT-J-STD-AIDS. 2018;29(3):227-236",43,YR,,M,Y,,,20180327,,OT,AU,AU,EFAVIRENZ.,Fanconi syndrome,146853581,OT,,,,,,,,,146853581,1,Antiretroviral therapy
14686541,146865411,1,I,20180221,,20180326,20180326,DIR,,,FDA-CTU,,40,YR,,M,N,64.3,KG,20180319,Y,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DF,Alanine aminotransferase increased;Aspartate aminotransferase increased;Blood albumin decreased;Blood alkaline phosphatase increased;Blood bicarbonate decreased;Blood chloride increased;Blood creatinine decreased;Blood glucose increased;Hepatotoxicity,,,146865411,HP,146865411,1,20180110,20180221,,,146865411,1,Kaposi's sarcoma
14690423,146904231,1,I,,20180314,20180328,20180328,EXP,,PT-MYLANLABS-2018M1018156,MYLAN,"CARDOSO C, TRIGO D, PACHECO P.. HIPERTENSAO PULMONAR NA INFEC?AO VIH/SIDA: UMA DOEN?A RARA.. VER CLIN HOSP PROF DR FERNANDO FONSECA. 2016;4 (1/2):41-44",62,YR,,F,Y,,,20180319,,MD,PT,PT,TENOFOVIR + EFAVIRENZ + EMTRICITABINE,Condition aggravated;Drug ineffective;Dyspnoea;Fatigue;Hypoxia;Product use in unapproved indication,146904231,DE,,,,,,,,,146904231,1,Pneumonia
4159551,41595514,4,F,20040125,20180217,20040625,20180302,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-12618450,BRISTOL MYERS SQUIBB,,19,YR,,F,Y,53,KG,20180302,,OT,FR,FR,SUSTIVA,Abortion induced;Labelled drug-drug interaction medication error;Pregnancy;Pregnancy with implant contraceptive;Therapeutic response decreased,41595514,OT,,,41595514,1,20031215,20040322,,,41595514,1,HIV infection
6753908,67539088,8,F,20060602,20180130,20080911,20180208,EXP,,CA-MERCK-0809CAN00002,MERCK,,44,YR,,M,Y,,,20180208,,OT,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,67539088,OT,,,67539088,1,20060602,20070522,,,67539088,1,HIV infection
6950326,69503265,5,F,20080401,20180202,20090324,20180207,EXP,,FR-GILEAD-2009-0020926,GILEAD,,,,,F,Y,,,20180207,,CN,FR,FR,SUSTIVA,Foetal exposure during pregnancy;Heart disease congenital,69503265,OT,,,69503265,1,20051201,20071211,,,69503265,1,HIV infection
7301762,73017622,2,F,20080422,20180202,20100302,20180207,EXP,,FR-GILEAD-2009-0020925,GILEAD,,30,YR,A,F,Y,,,20180207,,MD,FR,FR,SUSTIVA,Abortion induced;Maternal exposure during pregnancy,73017622,OT,,,73017622,1,20051201,20071211,,,73017622,1,HIV infection
7302622,730262230,30,F,,20180306,20100302,20180315,EXP,,CA-MERCK-0907CAN00093,MERCK,,52,YR,,M,Y,,,20180315,,CN,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Extraocular muscle paresis;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,730262230,OT,,,730262230,7,200802,,,,730262230,1,HIV infection
8533595,85335953,3,F,201006,20180207,20120427,20180212,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-16536534,BRISTOL MYERS SQUIBB,,41,YR,,M,Y,,,20180212,,OT,CA,CA,SUSTIVA,Drug interaction;Viral load increased,85335953,OT,,,85335953,1,1999,,,,85335953,1,Product used for unknown indication
8764293,87642934,4,F,20120227,20180216,20120831,20180221,EXP,,GB-GILEAD-2012-0060486,GILEAD,,27,YR,A,F,Y,46.89,KG,20180221,,CN,US,GB,SUSTIVA,Abortion induced;Maternal exposure during pregnancy;Off label use,87642934,OT,,,87642934,1,2011,,,,87642934,1,HIV infection
8784344,87843445,5,F,20120227,20180216,20120913,20180221,EXP,,GB-GILEAD-2012-0060487,GILEAD,,,,,F,Y,,,20180221,,CN,US,GB,SUSTIVA,Foetal exposure during pregnancy;Turner's syndrome,87843445,CA,,,87843445,1,20120227,,,,87843445,1,HIV infection
